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Dedication 
 
 
 
 
 
 
All women who have suffered and, in the worst case, died from breast cancer  
  
ABSTRACT 
Aims: The primary aim of this thesis was to examine the potential relationship between 
indirect markers of exposure to hormones during pregnancy and the risk of and survival from 
breast cancer, with special emphasis on young patients. Our specific objectives were as 
follows: to determine whether the association between placental weight and offspring size, on 
the one hand, and maternal mortality from breast cancer, on the other, are influenced by 
tumor characteristics; to examine the association between birth weight and risk of breast 
cancer in the female member of opposite-sexed twins; and to investigate whether familial 
factors influence previously reported association between reproductive factors and risk of 
breast cancer.  
Methods: Based on the Swedish Quality Register of Breast Cancer, two different cohort 
studies were designed in the Stockholm-Gotland and Uppsala-Örebro regions, where records 
on characteristics of breast cancer have been collected since 1992. The first cohort was 
restricted to women who had a pregnancy between 1982 and 1989, and subsequently 
developed breast cancer. The cohort included 1,067 subjects and 180 deaths, and was 
conducted to investigate if placental weight is associated with maternal risk of dying from 
breast cancer, taking tumor characteristics into account. In the second study, we studied the 
possible association between birth weight and maternal risk of death from breast cancer, also 
taking tumor characteristics into account. We included 6,019 women who had a pregnancy 
between 1973 and 2008 and subsequently developed breast cancer, of whom 1017 died from 
the disease.  
Two case-control studies were also performed. In a nested case-control study, involving the 
female members of opposite sexed twin pairs, 543 cases and 2715 controls were included to 
investigate the potential association between offspring birth weight and risk of breast cancer, 
as well as a possible modifying effect of birth weight of the male twin sibling. Information 
on the twins (including birth weight, birth height, head circumference and gestational age of 
the females, and birth weight of the male co-twin) was extracted from the Swedish Twins 
Register and data on women diagnosed with breast cancer from the Swedish Cancer 
Register.  
A second case-control study examined the potential modifying effect of familial factors on 
the association between reproductive factors and the risk of breast cancer. All women who 
delivered between 1973 and 2010 and had a full sister were selected as the study population, 
using the Swedish Medical Birth Register. Information on breast cancer was obtained from 
the Swedish Cancer Register and sisters were identified using the Swedish Multi-Generation 
  
Register. The cases examined included all parous women diagnosed with breast cancer 
between 1973 and 2010 who were 50 years old or younger and had at least one sister who 
also gave birth during this same period. The two control groups were sister controls 
(including the sister without breast cancer and closest in age to the case) and population 
controls (all parous women without breast cancer with at least a full sister except those in the 
sisters control group). In total, 8,349 cases, 8,349 sister controls, and 1,053,688 population 
controls were used.  
Results: Our findings indicate that the association between higher placental weight in 
connection with the most recent pregnancy and maternal risk of mortality from 
premenopausal breast cancer is dependent on the receptor status of the tumor. A positive 
association was more pronounced in the case of ER-/PR- tumors, but we did not find a dose–
response association. Birth weight demonstrated no association with maternal mortality from 
premenopausal breast cancer, even in analyses stratified by the time that elapsed between 
pregnancy and cancer diagnosis, tumor stage, and receptor status. There was an inverse 
association between birth-weight-for-gestational age and mortality from premenopausal 
breast cancer among uniparous women. The nested case-control study of opposite-sexed 
twins did not reveal any statistically significant association between birth weight and risk of 
breast cancer. Furthermore, we observed no associations between other birth characteristics, 
including co-twin birth weight, and the risk of developing pre- or postmenopausal breast 
cancer.  
Our last study provided some evidence that the association between reproductive factors and 
maternal risk of breast cancer or between maternal factors and maternal risk of breast cancer 
may differ when using population or sister controls. We found that parity exhibited an inverse 
association to premenopausal breast cancer using population controls and was a risk factor 
using sister controls, suggesting a gene-environment interaction. Very preterm delivery (<31 
weeks) was associated with a higher breast cancer risk using sister controls than when 
population controls were used, also suggesting a gene-environment interaction.  
Conclusions: We found some, but no strong evidence in support of the hypothesis that 
higher hormone levels during pregnancy are associated with mortality from premenopausal 
breast cancer. The hypothesis was supported when placental weight was employed as indirect 
indicator of estrogen levels during pregnancy, although birth weight showed no such 
association. The more pronounced effect of placental weight among ER-/PR- tumors suggests 
that premenopausal hormonal exposure might exert a greater impact on such tumors. The 
association between parity and risk of premenopausal breast cancer was modified by a gene-
environment interaction, as was the association between gestational age and the risk of breast 
cancer.   
 
Keywords: Breast cancer, Premenopausal, Postmenopausal, Placental weight, Birth size, 
Tumor characteristics, Estrogen Receptor, Progesterone Receptor, Twin, Opposite-sex, Sister 
control, Population control 
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1. Introduction 
Breast cancer is the most common form of cancer among women worldwide and its incidence 
is increasing in all countries, being highest in high income countries (1). In Sweden, for 
instance, one in every eight women is diagnosed with breast cancer during her lifetime (2). 
Despite the declining mortality from breast cancer in high-income countries in recent 
decades, this form of cancer still kills women more than any other form in all nations (3).   
Estrogens and reproductive factors associated with exposure to estrogen e.g., low parity, early 
age at menarche, late age at menopause, and late age at the time of first pregnancy, are well-
known risk factors for breast cancer. During the course of life, women are exposed to 
different levels of estrogen, especially high levels during their fetal life and when they 
become pregnant. Thus, exposure during these latter periods may be particularly important 
for the development of breast cancer. The impact of reproductive factors on the risk of breast 
cancer has been examined in many studies and some researchers propose that these factors 
may also play a role in breast cancer mortality.  
Tumor characteristics, including stage, expression of hormone receptors and histopathology, 
are prognostic factors for the outcome of breast cancer, including mortality. Moreover, the 
expression of a group of hormone receptors may provide a better indicator than considering 
these receptors individually. Thus, at the twelfth St Gallen International Breast Cancer 
Conference an expert panel, introduced a new method for classification of breast cancer for 
therapeutic purposes based on a combination of the estrogen receptor (ER), Progesterone 
receptor (PR), and human epidermal growth factor-2 (HER2) (4). It seems likely that 
reproductive factors exert different impacts on the prognosis for breast tumors with different 
characteristics.  
The primary aim of the present thesis was to examine associations between indirect markers 
of antenatal exposure to hormones and the risk of and survival from breast cancer. Taking 
tumor characteristics into account, associations between pregnancy and offspring 
characteristics and maternal mortality from breast cancer were focused on in two 
investigations.  In another study, the possible relationship of birth characteristics and breast 
cancer risk in the female member of opposite-sexed twin pairs was explored.  Finally, the 
possible influence of familial factors on the relationship between reproductive factors and the 
risk of breast cancer was examined.  
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2. Background 
2.1 Epidemiology 
2.1.1 Incidence 
In 2012, breast cancer accounted for 25% of newly diagnosed cancers among women around 
the world (1), with the highest incidences in high-income countries (Figure 1) (5-7). In this 
same year, the age-standardized incidence of breast cancer in Sweden was approximately 108 
per 100,000 population (Figure 2) (8), comprising 30% of all female cancers (Figure 3)(2) 
and afflicting approximately 1 of every 8 Swedish women during their lifetime.    
 
Figure 1: Estimated age-standardized rates of the incidence and mortality from breast cancer (per 100,000 
populations) in different regions in 2012  
 
 
(Taken from Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. 
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC, CancerBase No. 11 [Internet]. Lyon, France: 
International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 04.04.2014, with 
permission from the publisher) 
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Figure 2: Age-standardized incidence of and mortality from breast cancer per 100,000 population in Europe in 
2012  
 
 
(Taken from Ferlay et al. European Journal of Cancer, 2013, with permission from Elsevier). 
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Figure 3: The relative frequencies of different form of cancer in Sweden in 2010  
 
 
 
 
 
 
The annual increase in breast cancer incidence in Sweden has been approximately 1.3% 
during the past 20 years (Figure 4)(2) .   
 
 
 
Figure 4: Overall cancer incidence in Sweden since 1960  
 
 
 
 
 
  
(Socialstyrelsen - The National Board of Health and Welfare, Official Statistics of Sweden, Statistics – Health and Medical Care, Cancer 
Incidence in Sweden 2010) 
(Socialstyrelsen - The National Board of Health and Welfare, Official Statistics of Sweden, Statistics – Health and Medical Care, Cancer 
Incidence in Sweden 2010) 
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2.1.2 Mortality 
In 2012, more than 14% of all cancer deaths in low-income countries were due to breast 
cancer (1).  In spite of the fact that the relative rate of mortality is lower in high-income 
countries, the higher incidence in these countries (90/100,000 women) than in low-income 
countries (30/100,000 women) means that the overall mortality from breast cancer is almost 
equal  (15/100,000 women) (3). In Europe, the risk of breast cancer mortality varies two-fold 
between countries (8). For example, the age-standardized mortality from breast cancer are 29 
and 28 per 100,000 population in Belgium and Denmark, respectively, but only 15 and 17 per 
100,000 in Estonia and Spain. In Sweden, the corresponding rate  is 20 per 100,000 (Figure 
2)(8), and the annual reduction during the last four decades is around 1% (9).   
 
2.2 Risk factors for breast cancer 
The incidence of breast cancer increases with age. Although one possible definition of aging 
is “the accumulation of cell mutations and tissue damage that leads to disease”, aging does 
not itself induce all such changes (10), but is rather thought to reflect of the occurrence 
different life-events. Thus, the risk of breast cancer may be influenced by genetic changes, 
exposures during prenatal and early life, reproductive factors and late-life exposures such as 
those associated with hormone replacement therapy and menopause. For example, in an older 
woman a low-grade breast cancer with good-prognosis in terms of progression might be 
caused by a lack of DNA genomic material on the long arm of chromosome 16 (11). Thus, 
the impact of risk factors such as age at menarche, the time of first pregnancy and of first full-
term pregnancy that changes with age (12, 13) may be due to long-term exposure to, e.g., 
estrogens,  rather than to increasing age itself. Even though the impact of certain risk factors 
for breast cancer such as a high body-mass index (BMI) increases with age, this might reflect 
physiological changes rather than simply increasing age.  
 
2.2.1 Familial factors  
2.2.1.1 BRCA1 and BRCA2 
Mutations in genes such as  BRCA1 and BRCA2 appear to be responsible for less than 10% of 
breast cancers (14, 15). Mutations in BRCA1, a tumor suppressor gene identified in 1990 and 
located on chromosome arm 17q (16), are rare in the general population (Table 1), but carried 
by approximately 5-10% of women diagnosed with breast cancer (17). Such mutations are 
also linked to an enhanced risk of ovary cancer.   
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Women in high-risk families (i.e., those with multiple cases of breast cancer across several 
generations) and who also carry a mutation in BRCA1 have a 80-85% risk of developing 
breast cancer during their lifetime, while the risk of women with the mutation but without 
such a family history is 55-70% (14).  In comparison to sporadic breast cancer, tumors 
associated with a mutation in the BRCA1 gene are more poorly differentiated, of higher stage 
and grade, do not express hormone receptors and human epidermal growth factor receptor-2 
(HER2) (Triple Negative Breast Cancer (TNBC)) and exhibit invasive ductal histology (15, 
18, 19). Most, but not all women with such a mutation are diagnosed with breast cancer at a 
younger age. 
 
Mutations in BRCA2, located on chromosome arm 13q, are known to be responsible for 
breast cancer in men, but are also linked to breast but not ovary cancer in women. Such 
tumors in women are well differentiated and express the estrogen receptor (ER)(15, 19). 
Although the risk of breast cancer is substantially higher among women who carry mutations 
in  BRCA1 or BRCA2, penetrance is not 100% i.e., not every carrier develops breast cancer 
(17).  
 
 
 
  
 
 
 
  
Table 1: The frequency of BRCA mutations among different populations  
(Taken from Breast disease, 2006. 23(1), James P. Evans, C´ecile Skrzynia, Lisa Susswein and Megan Harlanc, Genetics 
and the young woman with breast cancer, p. 17-29, Copyright (2005,2006), with permission from IOS Press) 
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2.2.1.2 Twins  
Compared with singletons, twins  are more commonly born preterm and with a low birth 
weight, due to the anatomy of the uterus and placental capacity (20).  A discordance in the 
birth weights of twin siblings is common, especially at older gestational ages.  
In addition, twin pregnancies are associated with higher and more varied levels of estrogens 
than singleton pregnancies (21-23). These levels are also higher in dizygotic (DZ) than in 
monozygotic (MZ) twin pregnancies (24). Since the placenta is the  main source of hormones 
during pregnancy, the higher levels of  estrogen in DZ twin pregnancies is probably due to 
the presence of two placentas. Since estrogen is a well-known risk factor for breast cancer, 
the higher levels of this hormone during pregnancy might elevate the risk of breast cancer 
(25).  
The female member of twins of opposite-sexes may also exposed to androgens produced by 
their male co-twin (26). Glinianaia and colleagues (27) have shown that the birthweight of the 
female in twins of opposite sex is higher than when both twins are female. It is thought that 
androgens are responsible for the weight difference between male and female fetuses in 
connection with singelton pregnancies (26). Androgens compete with estrogens for binding to 
sex hormone binding globulin (SHBG) (26) and might thereby increase the level of 
bioavailable maternal estrogens, perhaps enhancing the risk of breast cancer.  
 
2.2.1.3 Familial history 
Having a first-degree relative (sister, mother or daughter) who develops breast cancer doubles 
a woman’s risk of breast cancer (28, 29), and this risk is higher if the relative is the sister than 
the mother (Figure 5) (29-31).  More specifically, the meta-analysis by Pharoah and 
colleagues (29) revelad that the relative risk of developing breast cancer was 1.9 if any first-
degree relative had breast cancer, 1.8 in the case of daughters, 2.0 for mother and 2.3 for 
sisters, and highest among women with both a sister and mother with breast cancer (28). The 
elevated risk associated with a family history of breast cancer declines with increasing age 
(31-35). Based on  a large population-based set of Swedish data, Brandt and colleagues (31) 
concluded that women with a family history of breast cancer were diagnosed and died from 
this disease at a younger age than those without a family history (Figure 5).  
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2.2.2 Reproductive factors  
Since measuring estrogen levels throughout a lifetime is difficult especially during the 
reproductive period, various indirect indicators have been developed, including age at 
menarche, age at first pregnancy, age at menopause, parity, gestational age and comorbidities 
related to pregnancy, such as pre-eclampsia, eclampsia, gestational hypertension and 
gestational diabetes. The relevance of such factors for the present work are discussed below.  
 
  
 (Taken from Brandt, A., et al., Age of onset in familial breast cancer as background data for medical surveillance. British Journal of 
Cancer, 2009.  102(1): 42-47, with permission from publisher) 
Figure 5: Cumulative incidence of breast cancer and cumulative risk of death by breast cancer according to 
the type of family history. (A) Age at which women with a family history reach the cumulative risk of 
women lacking a family history at the age of 40 and 50 years for incidence. (B) Age at which women with a 
family history reach the cumulative risk of women lacking a family history at the age of 40 and 50 years for 
death from breast cancer. 
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2.2.2.1 Maternal characteristics 
2.2.2.1.1 Age at first pregnancy 
Later age at first pregnancy is a strong risk factor for breast cancer (12, 36, 37) and indeed,  
epidemiological studies have shown that each year of delay can increase the risk of breast 
cancer about 5% among premenopausal and around 3% among postmenopausal women (12). 
Being exposued to estrogen at a younger age could stimulate a higher proliferation of 
mammary cells which protect breast cells from being cancerous in future.  
 
2.2.2.1.2 Age at last pregnancy 
It has been reported that every 5-years increase in age at last pregnancy might elevate the risk 
of breast cancer by 5-8% (38, 39). However, Nechuta (40) did not find any association 
between these parameters. 
 
2.2.2.1.3 Parity 
Although one full-term pregnancy can reduce the overall risk of breast cancer during a 
woman’s lifetime (41, 42), childbirth has a dual effect.  There appears to be a short-term 
increase and a long-term decrease in risk after each pregnancy (43-45), effects that recur with 
each repeated pregnancy (45-47). With each full-term pregnancy, the risk of premenopausal 
breast cancer is reduced by 3%, while the reduction in postmenopausal breast cancer is 12% 
(12). 
The effects of parity, age at first pregnancy, and age at last pregnancy on breast cancer risk 
may interact. For instance, women with higher parity often experience their first pregnancy at 
a younger age or the long-term protective effect of pregnancy in women who have two 
children is more dominant among those who were pregnant at a younger age (47). Therefore, 
when investigating the influence of parity on risk of breast cancer, it is important to control 
for the age at the time of  pregnancy, the period that elapses between pregnancy and the 
diagnosis of breast cancer, and the intervals between pregnancies.  
 
2.2.2.1.4 Maternal weight, height and body-mass index 
Maternal body characteristics, including weight and height, have been associated with breast 
cancer risk in different studies. Some researchers tend combine these variables, e.g., in the 
Body-Mass Index (BMI, calculated as weight (in kilogram) divided by height (in meter
2
), and 
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categorized as under weight (<18.5), normal weight (18.5 to <25), overweight (25 to <30) 
and obese (≥30). The association between BMI and breast cancer risk varies with other 
factors, such as age. For example several investigations have shown that obesity protects 
against breast cancer among premenopausal women (36, 48, 49), but enhances the risk 
among postmenopausal women (48-51). A meta-analysis of 13 studies revealed that for each 
unit increase in BMI breast cancer risk  was reduced 2% in premenopausal and elevated 2% 
in postmenopausal women(52).  
It has been proposed that premenopausal women with a high BMI have fewer ovary cycles 
which reduces their estrogen levels and in turn lowers their breast cancer risk (48, 53). In 
contrast, and despite cessation of ovary function in postmenopausal women, a higher BMI 
involves production of more estrogen by body fat tissue, which increases the risk. Indeed, 
postmenopausal women with a higher BMI exhibit higher levels of estrone, estradiol and free 
estradiol (50), as well as a lower level of SHBG, which enhance the bioavailablility of 
estrogen (48).  
 2.2.2.2 Characteristics of pregnancy 
Pregnancy exerts a dual impact on breast cancer risk (43, 47), which increases during the first 
five years after pregnancy and declines thereafter (45, 47). Both the mother’s age at the time 
of  delivery and parity can influence this association. Albrektsen and colleagues (47) found 
that the short-term risk of uniparous women who deliver their first child before 25 years is the 
same as for nulliparous women, but those who give birth after 30 years exhibit on elevated  
risk of at least 15 years after delivery. Mothers who have two children and their second 
delivery happens at an age younger than 25 demonstrate a transient risk increase for breast 
cancer shortly after delivery and this adverse effect is more prolonged among older mother 
(>30 years of age). Apparently, age at third delivery is less important.  
 
2.2.2.2.1 Gestational age of the child at birth 
Estimation the precise gestational age (GA) i.e., the duration of pregnancy (55) from 
fertilization to delivery is virtually impossible. There are three indirect measures of  the GA: 
the time that elapses between the first day of the last menstrual period (LMP) and delivery; 
ultrasound; and neonatal estimation (56). GA of  <37, 37-42 and >42 completed weeks are 
commonly categorized as pre-term, term and post-term, respectively. Pre-term GA is 
subcategorized as <28 (extremely pre-term), 28-31 (very pre-term) and 32-36 weeks 
(moderate pre-term) (57).  
  11 
Since estrogen levels increase as pregnancy progresses, the GA provides an indirect 
indication of this level. For example, Mucci and co-workers (58) reported that estrogens level 
are higher during the 27
th
 than the 16
th
 week of pregnancy and, moreover, that this increased 
level is associated with a higher later risk of breast cancer in the female offspring. Other 
investigators have found elevated breast cancer risk  among offspring delivered before 32 
(59, 60) or after 40 weeks of pregnancy (36). Russo and colleagues (61) proposed that since 
mammary cells proliferate during the first and second trimesters of pregnancy and 
differentiate during the third, shortening pregnancy holds mammary cells in proliferation 
phase, which makes them more prone to malignancy.  
2.2.2.2.2 Placental weight  
The placenta, a fetomaternal multifunctional organ of pregnancy,  has an average length of 22 
cm and thickness of 2–2.5 cm, being thickest in the middle. Its mean weight at a gestational 
age 40 weeks is 678 (±134) or 690 (±135) grams for a female or male fetus, respectively (62). 
The main functions performed by the placenta are nutrition, transporting oxygen and nutrients 
to the fetus, excretion, immunity and regulation of the endocrine status, becoming the 
primary steroid-producing organ during pregnancy (63).  
During pregnancy, the placenta produces four dominant hormones, i.e., human chorionic 
gonadotropin (hCG), human placental lactogen (hPL), estrogen and progesterone.  Previous 
work has revealed that placental weight can serve as an indirect indicator of estrogen levels 
during pregnancy (25, 63-67) and that breast cancer risk increases with placental weight (36). 
Thus, women whose placenta weighed more than 700 grams had a 38% higher risk of 
developing breast cancer than those whose placental weight was less than 500 grams (36).  
 
2.2.2.3 Characteristics of the offspring 
2.2.2.3.1 Birth weight, height and head circumference  
It has been proposed that breast cancer may actually originate in utero (68). The level of  
estrogen, a well-known risk factor for breast cancer (see above), in the mother’s blood is 
almost 200 times higher during than before pregnancy and it has been suggested that this 
exposure may be associated with the risk of breast cancer. Given the difficulty of directly and 
continuously measuring estrogen levels during pregnancy, some proxy measures have been 
considered. For instance epidemiological studies have reported that birth size (including 
weight, height and head circumference) are correlated with level of hormones, including 
estrogens during pregnancy (63, 69, 70).  
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Most investigations have found a positive association between birth weight and breast cancer 
risk in the female offspring (67, 71-79), particularly in premenopausal cancer (77, 80-86), 
whereas others observed no such association (66, 87-90). A literature review (91) of  26 
relevant studies from 2000-2005 revealed that 16 found a positive association, three observed  
a positive, although not statistically significant association, and the remaining 7 found no 
association. In these studies the alteration in the risk of breast cancer with a birth weight of 
≥4000 versus ≤2500 grams ranged from 17% to 5-fold. Moreover, it has been reported that 
breast cancer risk  rises 9% for each 1000-grams increase in birth weight (92). Of the 14 
studies dealing specifically with the association between birth weight and risk of breast 
cancer among the premenopausal female offspring (91), 11 showed a significant positive 
association between birth weight and risk of breast cancer, 5 of them showed a positive trend 
and 4 a threshold effect. Among the 8 studies on postmenopausal cancer (91), only one study 
observed an association.  
Furthermore, offspring birth weight has also been associated with maternal risk of breast 
cancer. For example, Wohlfahrt and co-workers (25) have found that this risk is slightly 
higher (1.02, 95% CI 0.9-1.5) among mothers who deliver a heavy baby. In addition, 
Cnattingius and colleagues (36) found a positive association with risk of breast cancer among 
women who deliver two consecutive heavy babies (1.42, 95% CI 1.12-1.79), but that this 
elevation disappeared after adjusting for placental weight. 
In addition to birth weight, an association between birth height and risk of offspring breast 
cancer has been reported (76), a stronger independent association than for birth weight or 
head circumference (76). It has been reported that this risk is 17% higher for women whose 
birth height was ≥51 cm and 11%  higher for those whose head circumference was 31 cm 
(76).  
2.2.2.3.2 The Ponderal index 
Ponderal (PI) or Rohrer’s index, an indicator of fetal nutritional status (63), is defined as the 
ratio between birth weight (in gram) divided by birth length (in centimeter
3
)*100.  Given the 
correlation between birth weight and height (76, 93), this could provide a suitable index of 
the combined effect of these two variables. This composite indicator of offspring nutritional 
status, which might be independent of race, gender and birth order (94), may be better than 
birth weight alone (95), as well as providing a useful indicator of fetal growth (94). PIs are 
categorized as low (PI<10%), appropriate (10%<PI≤90%) or high (PI>90%) (94).   
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PI is associated with maternal levels of estrogens during the reproductive period and 
pregnancy. Jasienska and colleagues (95) concluded from the association between PI and the 
level of estradiol (E2) that a higher PI may indicate a higher breast cancer risk. Moreover, 
Kaijser and co-workers (70) observed a positive association between PI and estriol levels 
(E3) during pregnancy.  
2.2.2.3.3 Birth weight for gestational age (BW/GA) 
BW/GA is defined as the ratio between the actual birth weight and that expected for the same 
gestational age and sex. Therefore, BW/GA might provide a better retroactive indicator of 
fetal growth than birth weight alone. This index can be categorized as very small for 
gestational age (VSGA) (<3%), small for gestational age (SGA) (3-<10%), appropriate for 
gestational age(AGA) (10-90%), i.e., normal (96, 97), large for gestational age (LGA) (91-
97%) and very large for gestational age (VLGA) (>97%) (98). Nechuta and colleagues (40) 
observed that women whose offspring had a BW/GA of <10% demonstrated a lower risk of 
breast cancer among those who experienced their last pregnancy at the age of 30 or older 
(0.82, 95% CI 0.59-0.98).  
 
2.2.2.4 Exposure to hormones  
2.2.2.4.1 Estrogen 
The steroid hormone group of estrogens induces responses in the reproductive tract, 
mammary tissue, and pituitary gland during the reproductive process, as well as playing roles 
in non-reproductive processes, such as bone formation and cardiovascular health (99). The 
ovary is the main source of estrogen during most of the reproductive period, except during 
pregnancy, when the placenta is the main source. In premenopausal women, the serum levels 
of estrogens, mainly in the form of estradiol (E2), is 100 pg/ml during the follicular phase and 
approximately 600 pg/ml at the time of ovulation, but levels of estrogen, mainly estriol (E3) 
elevats to nearly  20,000 pg/ml during pregnancy. The level of estrogen falls to less than 20 
pg/ml after menopuase, when estrone (E1) becomes the dominant forms. The growth and 
differentiation of ductal cells in breast tissue are stimulated by estrogens, which also plays an 
indirect role in the development of the mammary glands (100).  
 
Estrogen normally binds to SHBG (approximately 37%). “Non-SHBG-bound hormone”  
(approximately 2% free estrogen) and estrogen bound to albumin (approximately 61%) are 
referred to as bioavailable (101) and affect target cells, including both normal and malignant 
breast cells. The serum concentration of bioavailable estradiol is thought to be more strongly 
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associated with the risk of breast cancer than the total level of estradiol (101, 102). Estrogen 
bound to SHBG is also available to responsive tissues, where it reduces cell proliferation, so 
that a reduction in the binding capacity of SHBG results in more rapid proliferation in 
steroid-sensitive tissues such as breast cells (101). This binding capacity is lower in 
postmenopausal than premenopausal women (103) and an association between the levels of 
SHBG and ER has been detected in connection with postmenopausal, but not premenopausal 
breast cancer (103). From conception until the 30
th
 week of pregnancy, the level of SHBG is 
6 to 10-fold higher in pregnant women than in those who are not pregnant (104). 
 
A number of investigations on the difference in serum estrogen levels between pregnant 
compared and non-pregnant women and its association with the risk of breast cancer have 
been published. One review (105) concluded that the mean estrogen level in premenopausal 
women is 12% higher in those diagnosed with breast cancer, while another similar review on 
postmenopausal women arrive at a 15% higher value for those with breast cancer (106). A 
meta-analysis on 9 prospective studies revealed that high levels of serum estrogen is 
associated with higher risk of postmenopausal breast cancer (107). It has also been reported 
that the elevated level of estrogen during the first trimester of pregnancy is positively 
associated with the risk of developing breast cancer before 40 years of age, but that this 
association becomes negative at more advanced age (108). Moreover, an European study 
observed that the estrogen levels in women diagnosed with breast cancer is higher than in 
control subjects three year prior to diagnosis (109). The association between estrogen and 
breast cancer risk appears to be independent of family history (110).  
 
2.2.2.4.2 Progesterone 
Progesterone is secreted by the ovary during most of the reproductive period, but primarily by 
the corpus luteum and placenta during pregnancy (63). The main responsibilities of 
progesterone are to prepare the uterine muscles for implementation of the fertilized ovum and 
then support the pregnancy by inducing the proliferation and differentiation of uterine 
muscles to protect early embryonic development. A possible association between the level of 
progesterone and risk of breast cancer remains unclear: certain reports have shown a negative 
association with premenopausal women (109, 111), while no association was found for 
postmenopausal women (112) or all cases of breast cancer (108, 112). However, estrogen and 
progesterone might interact to elevate the risk of breast cancer; the so-called (estrogen plus 
progesterone hypothesis) (109).  
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2.2.2.4.3 Androgens 
Since androgens are the obligatory precursors of all endogenous estrogens and may play a 
role in cell growth and proliferation, they might also influence breast cancer risk, either 
directly and/or indirectly (113, 114). Their ability to stimulate the growth and proliferation of 
cells might affect this risk directly while conversion to estrogens represents indirect 
involvement. Postmenopausal breast cancer exhibits a positive association with higher levels 
of androgens (102, 107, 109, 112) and reanalysis of 9 prospective (107) and the other studies 
(109) reveals that this is an independent association. Tumors that express both ER and PR are 
correlated with higher concentrations of androgens, including testosterone, androstenedione 
and  dehydroepiandrosterone sulfate, but not those that  lack either or both of these receptors 
(112). 
 
Among the few studies on the association between androgen level and risk of breast cancer in 
premenopausal women, two (115, 116) reported a positive correlation. Some studies report 
that this association is more pronounced in the case of invasive tumors (110, 117) and 
ER+/PR+ patients (110, 118), but the underlying mechanism(s) remains unclear.  
 
2.2.2.4.4 Insulin-like growth factor 1(IGF1) 
In the 1980’s, it was postulated that IGF1, a peptide that stimulates mitosis and inhibits 
apoptosis in humans, is involved in the development of breast cancer (119). The serum 
concentration of  IGF1 is higher in women with breast cancer than in those without breast 
cancer (120, 121). A review of 17 studies in 12 countries (119) concluded that the IGF1 level 
is positively associated to the risk of breast cancer and that this association is relatively 
unchanged by menopause. The level of IGF1 also positively associated with height, age at 
first pregnancy, moderately increased weight, and moderate alcohol consumption.   
 
2.2.2.4.5 Prolactin 
Prolactin, secreted by the pituitary gland, stimulates cell proliferation in the normal breast 
before and during pregnancy, as well as lactation following pregnancy. Certain investigators 
report that the serum level of prolactin is reduced after the first pregnancy (122). Moreover, 
this level is inversely correlated to age at first birth and the age when breastfeeding is begun 
(123). It has been proposed that prolactin is an important factor in the etiology of breast 
cancer, stimulating the proliferation of and inhibiting apoptosis in tumor cells (124, 125). 
Several studies have shown a positive association between the prolactin level and risk of 
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breast cancer among postmenopausal women (126-128), and one study (128) reported a 
similar association in premenopausal women.  
 
2.3 Prognosis for women with breast cancer 
Thanks to improved diagnosis, better staging of the tumor at the time of diagnosis and more 
effective treatment, mortality from breast cancer has been declining since the 1990s (129). 
Although many factors, such as those associated with reproduction are well-known risk 
factors for breast cancer (see above), their influence on breast cancer mortality is not as well 
known.  
 
2.3.1 Genetic and environmental factors  
2.3.1.1 BRCA1and BRCA2 
Few investigations have focused on the impact of mutations in BRCA1 and BRCA2 on 
survival after developing breast cancer. Four of these studies observed no impact (130-133). 
In contrast, Robson and colleagues (134) reported that carrying a BRCA1 mutation reduces 
survival, but only among women who have undergone breast-conserving treatment in 
connection with invasive breast cancer. 
 
2.3.1.2 Family history  
Some previous investigations have revealed that mortality from breast cancer is higher among 
women who have a positive family history (Figure 5) (31, 135, 136) , an effect that is age-
dependent, being high pronounced at younger ages (136). Moreover, mortality, is higher 
among women whose sister, rather than mother was diagnosed with this malignancy (31). 
Certain other studies reported a higher survival of breast cancer in family history positive 
patients (137-140). Adjustment for potential confounders has confirmed that this favorable 
influence of a positive of family history is an independent effect (138). In a japenease study, 
women with a positive family history had smaller tumors, that expressed higher levels of 
ER+ and  lower levels of HER2, as well as less lymph node involvement (141). However, the 
mechanism(s) underling the lower mortality from breast cancer among women with a 
positive family history is still not clear.  
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2.3.2 Reproductive factors 
2.3.2.1 Maternal characteristics 
2.3.2.1.1 Age at the time of diagnosis   
Age at diagnosis has been proposed to be a valuable prognostic factor for breast cancer 
survival. Breast cancer is relatively uncommon among young women, and only 15-25% of 
these patients are in their thirties or forties (142). Although the definition of “young” varies 
(49, 143), breast cancer in younger women is known to involve larger tumors, at a higher 
stage, lower expression of both ER and PR, higher levels of HER2, more extensive 
involvement of lymph nodes (144, 145), and poorer prognosis (146, 147).  
 
It has been suggested that breast cancer should be categorized at the time of diagnosis as 
either premenopausal or postmenopausal. Some studies divide women with breast cancer into 
those whose are 50 or younger and those who are older, which corresponds roughly these 
same two categories (146, 148, 149). Although breast cancer is more frequent among 60-70-
year old women (Figure 6), the disease is more often aggressive among women younger than 
50 (Table 2). Moreover, mortality declines with increasing age at the time of diagnosis.  
 
The inverse association between age at the time of diagnosis and the risk of dying from breast 
cancer has been addressed in several publications (150-152). Han and Kang (143) observed 
that breast cancer mortality risk increased by 5% for each year of reducing in age among 
women younger than 35, but not for those between 35 and 50 years of age. In fact, they found 
that the pattern risk of mortality from breast cancer differs for women younger than 35 and 
those who are older and therefore suggested that 35 years is a suitable cutoff for young cases 
of breast cancer. Despite these findings, age at the time of diagnosis is not considered to be an 
independent prognostic factor (142) and the higher mortality risk among younger patients 
might reflect the more serious nature of their tumors (142, 152).   
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Table 2: Pathological features of breast cancer in premenopausal women 
Figure 6: Age distribution of women with breast cancer in Sweden in 2010  
 
(Socialstyrelsen - The National Board of Health and Welfare, Official Statistics of Sweden, Statistics – Health and Medical Care, Cancer 
Incidence in Sweden 2010) 
 
(Reproduced from Vetto J. et al. Current Problems in Surgery 944–1004 ) with the permission of the publisher) 
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2.3.2.1.2 Age at first pregnancy 
A younger age at first pregnancy in premenopausal women is associated with a higher breast 
cancer mortality rate (153-155). Although a study involving a population of more than 
800,000 revealed that the mortality from premenopausal breast cancer was higher among 
women who had their first pregnancy after 30 years (153), other studies have reported that the 
risk of mortality from breast cancer is higher among women younger than 20 years at their 
first pregnancy than those between 20 and 24 (154, 155). Thus, although high age at first 
pregnancy is a risk factor for breast cancer, age at first pregnancy appears to be somewhat 
inversely associated with breast cancer mortality (155). It has been postulated that lower age 
at first pregnancy can prevent less aggressive forms of breast cancer. If so, the more 
aggressive forms that do develop might explain the higher risk of mortality associated with 
lower age at first pregnancy (154). 
2.3.2.1.3 The time that elopes between pregnancy and the diagnosis of breast cancer: 
Pregnancy-associated breast cancer (PABC) is defined as disease diagnosed during 
pregnancy or within 2 years after delivery (156). Several previous examinations have found 
that the risk of breast cancer is increased during the two years immediately after delivery, and 
some have shown that survival among women whose breast cancer is diagnosed during this 
period is reduced (156-165). For example Philip and co-workers (163) found that the risk of 
mortality from breast cancer was 1.7 for women diagnosed during the two years after 
pregnancy and 0.9 for those diagnosed five or more years after. Although there is one report 
that this risk is higher among women diagnosed within the first year after pregnancy (164), a 
Swedish study found maximal risk 4-6 months after pregnancy (156).  
The reduction in breast cancer mortality risk associated with a longer time interval between 
last pregnancy and diagnosis persists for more than 10 years among women who were 
younger than 20 at their first pregnancy(154). No association between the time between the 
last pregnancy and diagnosis of breast cancer and survival was seen among postmenopausal 
women (157).  Although certain studies claim that the overall survival of cases with PABC 
and other is the same (166), Philips and colleagues (163) concluded that this survival 
increases  by 8% for each year that elapses after pregnancy; while another report (167) 
presented a corresponding values of 15%, although the sample size  was small in this latter 
case.  
Although it is unclear why the risk of mortality from breast cancer falls as more time elapses 
after delivery, one possible mechanism could involve changes during pregnancy, particularly 
in hormonal status (168) which might stimulate tumor growth and/or select for the growth of 
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more aggressive cancer cells (164). In addition, a longer delay before accurate diagnosis due 
to the increased density of the breasts of younger lactating women may play a role (163). It 
has also been proposed that the characteristics of the tumor are important in this connection. 
Tumors diagnosed during first two years after pregnancy have been reported to be 
particularly aggressive (164, 165, 168) with a higher stage (160), an axillary node–positive 
nature (160, 163, 166), no expression of ER (159, 163, 166) or PR (159, 160, 166), a higher T 
class (159, 166), expression of p53 (160), a high mitotic count (160), with a fraction of cells 
in S phase (160), and a higher grade (160, 166). Thus, the association between diagnosis of 
PABC and risk of mortality from breast cancer has not been reported to be an independent 
prognostic factor (166) but, rather, to be confounded by the characteristics of the tumors 
(164). Certain other investigations suggest that additional, unknown characteristics of the 
tumors or pregnancy may exert an impact on this association (163). 
 
2.3.2.1.4 Parity 
Higher parity is associated with more extensive breast cancer mortality among 
premenopausal women (42, 157, 160, 161, 169, 170). For example, Olson and co-workers 
(42) found that the risk of such mortality is higher among women with three or more children 
than among nulliparous women. In contrast, certain reports indicate that parity either 
promotes (171) or has no effect on mortality from breast cancer, neither among 
premenopausal nor among postmenopausal women (155, 164). The tumors of parous women 
demonstrate a higher stage at the time of diagnosis, positive nodes and expression of p53 
(160, 169). 
 
2.3.2.2 The characteristics of pregnancy 
2.3.2.2.1 Maternal weight, height and BMI 
Some studies, including a literature review (48, 161, 172-174), show that most, but not all of 
the reports indicate that both overall and five-years survival from breast cancer is lower in 
pre- and postmenopausal women with higher BMI. Obesity is associated with cancer 
exhibiting less favorable features, including more nodule involvement (175) and a higher 
stage (176). In addition, a Norwegian study has shown that high body weight is associated 
with larger diameter, especially in the case of ER- and PR- negative tumors (177). Moreover, 
the risk of developing inflammatory breast cancer, the most lethal form, is higher among both 
pre- and postmenopausal women with higher BMI (48). In addition, all modalities of breast 
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cancer treatment, including surgery, radiotherapy, chemotherapy and hormone treatment, are 
reported to be adversely affected by obesity (48, 172).  
 
2.3.2.2.2 Placental weight 
The association between placental weight, suggested as an indicator of estrogen levels during 
pregnancy (58, 70, 178), and the risk of breast cancer has been examined by some 
investigators, but only one study has focused on the association between placental weight and 
breast cancer mortality risk. In this Swedish study, Larfors and colleagues (179) found that 
women whose placenta weighed 700 grams or more had an enhanced mortality risk, although 
they did not observe any significant association with other subgroups of placental weight. 
The association observed was more pronounced among uniparous women and those 
diagnosed with breast cancer during first two years after delivery.  
 
2.3.2.3 Characteristics of the offspring 
2.3.2.3.1 Birth size 
Few investigations have examined the possible association between birth size and later 
offspring mortality from breast cancer. Sanderson and colleagues (180) reported that a birth 
weight of more than 4000 grams is associated with a higher subsequent breast cancer 
mortality risk. In addition,  Norwegian researchers observed that a birth height of more than 
52 cm was associated with a higher risk of mortality, but found no such associations with 
offspring birth weight or PI (181), which is in agreement with another study (155). Sovio et 
al. (182) have reported that the risk of mortality from breast cancer is increased 29% by an 
increase in birth weight by one standard deviation, with a weaker association for PI. 
The possible association between offspring size and maternal breast cancer mortality risk has 
also been explored. Smith and co-workers (93) observed higher maternal mortality in 
association with higher PI, but no relationship to offspring birth weight or height. A meta-
analysis revealed no association between birth weight and maternal mortality from breast 
cancer (183).  
 
2.3.2.3.2 Gestational age  
Little has been reported on the possible association between gestational age and mortality 
from breast cancer. Sanderson et al. (180) found no such association, whereas Sovio (182) 
reported 14-17% increased breast cancer mortality risk with an increase in gestational age by 
one standard deviation. 
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2.3.2.4 Tumor characteristics 
2.3.2.4.1 Stage 
Since 1953, solid tumors are categorized with staging system (184) (TNM, the latest edition 
of which was described in 2010 by the International Union Against Cancer (uicc) (185)), 
based on the size of the tumor (T), involvement of lymphatic system (N) and distribution 
throughout the body metastasis (M) as the primary prognostic factors. Based on this TNM, 
the American Joint Committee on Cancer (AJCC), has introduced a specific system for 
staging of breast cancer, (latest edition in 2009) (186), which is also used.   
 
Various investigations have revealed that larger size, involvement of nodes and distant 
metastasis are poor prognostic factors for cancer. Higher tumor stage is associated with 
higher mortality (42, 187-189), but tumor size, nodule involvement and distant metastasis 
might valuable prognostic factors for individual breast cancers as well (42, 189). Previous 
findings indicate that axillary node involvement is the most independent indicator of overall 
survival from breast cancer (190), even if there is discordance between tumor staging and 
nodule involvement (191). Despite worldwide routine use of the TNM staging system for 
selecting the optimal therapeutic approach, there are suggestions that this system requires 
more refinement in order to become a really useful guideline for therapy (190, 192, 193).  
 
It has been reported that the prognostic value of tumor size, nodule involvement and tumor 
grade decreases progressively with time (194, 195), although others suggest long-term 
effectiveness of these prognostic factors (196). One investigation including operable breast 
cancer cases found that the value of these prognostic factors tended to disappear after 10 
years and that they were not related to mortality risk after 15 years (194).  
 
2.3.2.4.2 Hormone receptors 
The presence or absence of hormone receptors, including the ER and PR, individually or 
together has been suggested to be prognostic- and predictive factors for breast cancer. This 
expression increases with the age of the patient (197, 198) and the distribution of the 
receptors changes during the years following breast cancer diagnosis (199). Karlsson et al. 
(200) compared ductal carcinoma in situ with the subsequent nodule involvement found that 
15% of the cases with ER expression and 30% of the cases with PR expression were changed 
in subsequent local relapse. Moreover, the prognostic value of hormone receptors appears to 
be short-time, and decreases with a long follow-up time (201-203). Bardou and colleagues 
(203) explained that, although women whose tumor is ER+/PR+, ER+/PR- or ER-/PR+ have 
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better survival than those with ER-/PR- tumors, this prognostic value disappears after 5 years, 
whereafter it becomes difficult to predict the future development of the tumor based on their 
receptor status. Notwithstanding, researchers still believe that breast cancer can be considered 
to be distinct diseases characterized by their hormone receptor status (204-208). 
 
2.3.2.4.2.1 Estrogen receptors (ERs) 
Estrogen receptors belong to a superfamily of nuclear receptors, including receptors for sex 
steroids, thyroid hormone and retinoid (99). The two different isoforms of ER, ERα and ERβ, 
are encoded on chromosomes 6 and 14, respectively (202, 209). A broad spectrum of tissues 
express ERα and ERβ; ERα  is expressed at a higher level in the breast, prostate (stroma), 
ovary (theca cells), testis (Leydig cells), and liver, while ERβ  is expressed more strongly in 
the prostate (epithelium), colon, testis, ovary  (granulosa cells) and bone marrow (210).  
 
In breast tissue, ERs are expressed by both normal and malignant cells.  About 20%  of the  
Terminal Duct Lobular Units (TDLU) in the breast of premenopausal women express the ER,  
a value that doubles during the follicular phase (211). The average extent of expression of ER 
by the TDLU cells of postmenopausal women is approximately 50%(211).  
 
Expression of  ERs increases dramatically in early hyper-proliferative premalignant lesions 
(211). Approximately 75% of breast tumors express ERs (211) with an elevated ratio of ER+ 
to ER- cells in comparison to normal breast tissue. Moreover, higher expression of  ER is 
associated with higher breast cancer survival (212, 213).  ER+ tumors tend to develop in 
older women (peaking of 70 years at age (214)), whereas ER- tumors tend to develop at an 
earlier age (peaking at 50) (49).  Mortality from premenopausal ER+ breast cancer is higher 
in women younger than 35 than in older women (49).  
 
2.3.2.4.2.2 Progesterone receptors (PRs) 
Progesterone receptors belong to a nuclear or intracellular superfamily of ligand-dependent 
transcription factors (215, 216). After binding progesterone, PR changes conformation and is 
translocated to the nucleus, where it interacts with DNA to mediate the effects of 
progesterone (217, 218). In most target tissues, expression of PR is stimulated by estrogen 
(202) and reduced by progesterone.  
 
The two isoforms of PR, PR-A and PR-B, are encoded by the same gene but their expression 
is initiated by different promoters (202, 215, 216, 219). Some studies suggest that expression 
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of PR is stimulated by atypia and increasing ratio of PR-A to PR-B, which is almost one in 
normal breast tissue, but varies extensively in malignant cells (220, 221). Approximately 
60% of invasive breast tumors express PR-A or B (216).  
 
2.3.2.4.3 Human epidermal growth factor receptor-2  
Human epidermal growth factor receptor-2 (HER2) is a transmembrane tyrosine kinase 
receptor encoded on chromosome 17q21. HER2 is overexpressed in approximately 20-25% 
of invasive breast tumors as a result of gene amplification (222). This receptor has a role in 
regulating cell proliferation (50).  
 
In newly diagnosed patients, HER2-positive breast cancer has a worse prognosis (50) and this 
factor may thus play a role in decision-making about treatment (223, 224). Such tumors are 
relatively resistant to endocrine therapy (222, 224, 225). Approximately 10% of primary 
HER2+ tumors becomes HER2- upon relapse (200). It has been reported that 6% of HER2- 
tumors becomes HER2+ during tumor progression and that 19% of HER2+ tumors becomes 
HER2-, although sample number in this case was small (226). The American Society of 
Clinical Oncology has suggested that HER2 expression should be used routinely as a 
prognostic- and predictive marker for breast cancer (222, 227) 
 
2.3.2.4.4 Estrogen and progesterone receptors together 
In light of the heterogeneity of breast cancer, it has been proposed that categorization should 
be based on expression of both ER and PR (207), which has a better and more independent 
prognostic value than their individual levels of expression (228, 229). ER+/PR+ tumors have 
a better prognosis than the other types of breast cancer (ER+/PR-,  ER-/PR+ or ER-/PR-)(71, 
228, 229), exhibiting smaller size, more favorable grade and better cancer-specific survival 
than ER-/PR- tumors (71). Among breast tumors, 60% are ER+/PR+, 15-20% ER-/PR-, 15-
20% ER+/PR-, and less than 5% ER-/PR+ (71, 206-208). 
 
Receptor status is associated with a number of factors, including maternal age, menopausal 
status, age at first pregnancy, nulliparity and age at menarche. ER+/PR+ tumors are much 
more common among older women, whereas ER-/PR- tumors are more frequent among 
younger patients (230). Thus, premenopausal women are diagnosed more after with ER-/PR- 
tumors, while ER+/PR+ tumors are more frequent after menopause (71). Some studies 
indicate that higher age at first pregnancy, nulliparity and later age at menarche exert stronger 
effects on the risk of developing ER+/PR+ than to ER-/PR- tumors in postmenopausal 
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women  (207, 231). Others have shown that higher maternal BMI (232, 233) increases the 
risk of ER+/PR+ breast cancer. However, another investigation reported no influence of  
menstrual or reproductive characteristics and familial history on ER+/PR+ and ER-/PR- 
tumors (205).  
 
2.3.2.5 Classification according to St Gallen procedure   
In 2011, an expert panel of the 12
th
 St Gallen International Breast Cancer Conference 
introduced a new procedure for classification of breast cancer into 5 different subcategories 
on the basis of hormone receptor expression and epithelial cellular origin for therapeutic 
purposes (Table 3) (4). Tumors are categorized as follows:Luminal A: ER+ and/or PR+, low 
Ki56 (<14%), HER2-. Luminal B: ER+ and/or PR+, high Ki56 (>14%), HER2-; or HER2+ 
with any expression of Ki56.  HER2+ (Erb-B2 or non-Luminal): ER- and PR- but HER2+. 
Triple Negative Breast Cancer: ER-, PR- and HER2-. 
 
 
  
Table 3: The luminal classification of breast cancer 
(Reprinted from Goldhirsch, A., et al., Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St 
Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 2011. 
22:1736-1747. With permission from the publisher) 
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Luminal A tumor has a more favorable prognosis than the Luminal B subtype. TNBC tumors, 
which constitute 10-20% of breast cancer tumors, have a higher mortality rate and higher 
probability of distant metastasis than other subtypes of breast cancer (4, 51, 234).  There is 
some discordance between the expression of factors in the original breast tumor and in lymph 
node metastases, as well as in the original tumor and relapse. For example, Falck and 
colleagues (234) showed 11% discordance between original tumors  and with lymph node 
metastases and 16% of original Luminal A tumors were of a better subtype than lymph node 
metastases. Wilking and colleagues (226) found that in 15% of patients with HER2+ or 
HER2- original breast cancer, the recurrent tumor was of the opposite type. Moreover, 
Lindström and co-workers (235) found that 32.4% of ER+, 40.7% of PR+ and 14.5% of 
HER2+ original tumors change to the negative status upon relapse.  
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2.4 Mechanism(s) underlying the development of breast cancer 
2.4.1 Normal maturation of the breast 
Mammary glands in women start to develop at the puberty, when the ductal structure begins 
to enlarge and branch by the beginning of the menstrual cycle. At onset of puberty, the 
epithelial cells in the ducts start to proliferate and form a tree-like pattern from the nipple to 
the end of the buds. Terminal Ductal Lobular Units (TDLU) develops and become more 
complex during subsequent menstrual cycles. The tree-like structures in the mammary gland 
are lined by epithelial cells and are surrounded by myoepithelial cells, which are in touch 
with basement cells. The TDLUs are embedded in fat tissue and surrounded by stromal cells 
(Figure 7) (216, 236, 237). 
 
  
 
 
 
 
Development of the breast normally starts 3 years prior to menarche. Many hormones, and 
especially the female sex steroids estrogen and progesterone, are required for the proliferation 
and development of mammary cells. The minimal hormonal requirement in this connection 
includes estrogen, progesterone and prolactin or growth hormone (237). Estrogen produced 
by the ovary is primarily responsible for the development of breast stroma, growth of the 
ducts, and deposition of fat; while progesterone promotes lobular growth, alveolar budding 
and alveolar secretory changes. Both estrogen and progesterone are necessary for complete 
maturation of the ductal alveolar system (238).  
 
Figure 7: Structure of the mammary gland and terminal ductal–lobular unit (TDLU). 
(Taken from Dimri et al. Breast Cancer Research 2005 7:171-179. With permission from the publisher) 
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At onset of pregnancy, the epithelial cells of the breast begin to divide again, a process which 
continues until delivery.  The ductal trees expand and the number of ductules in the TDLUs 
increases during early pregnancy, and the ductules become mature to produce and secret milk 
during the last period of pregnancy and lactation. When lactation starts, epithelial DNA 
synthesis begins, but ends after lactation is completed, when the glands are switched off until 
onset of the next pregnancy. Thus, during pregnancy and during lactation, the breast tissue 
evolves from immature to fully developed (204, 237, 239). 
 
2.4.2 Tumorogenesis 
Histology reveals that the TDLU are the main origin of breast cancer in women. Moreover, 
since estrogen and progesterone receptors are expressed only in the luminal epithelial cells of 
these ducts, these cells could be in initial site of malignant transformation (204). Malignant 
cells may stay where they are, giving rise to Ductal Carcinoma In Situ (DCIS), the most 
common histological variant of the non-invasive stage of breast cancer. They may also 
penetrate the basal cells and extend to other parts of the body, resulting in, for example 
Invasive Ductal Cell (IDC), which accounts for 85-90% of all cases of invasive breast cancer 
(236).  
The endogenous levels of steroid hormones fall sharply after menopause, due to the cessation 
of ovarian activity. At this point, adipose tissue becomes the main source of estrogen (102, 
236). High levels of estrone (E1), the dominant form of the circulating hormone during 
postmenopausal period (102) is associated with a higher risk of postmenopausal breast 
cancer. Higher levels of estradiol and testosterone are also known to be associated with an 
enhanced  risk of breast cancer (126, 240).  
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3. Aim of the present study 
Main aim 
To examine the independent association of indirect markers of pregnancy hormone exposure 
with breast cancer risk and survival, with special emphasis on young patients. 
 
Aims of the individual studies 
 To investigate whether tumor characteristics modify the association between placental 
weight and maternal mortality from breast cancer. 
 
 To examine possible associations between offspring size at birth from the most recent 
pregnancy before diagnosis of premenopausal breast cancer and maternal risk of 
breast cancer mortality, taking tumor characteristics into consideration. 
 
 To explore the association between birth weight and offspring risk of breast cancer in 
females in opposite sexed twin pairs.  
 
To investigate whether prenatal exposure to androgens from a twin brother influences 
the risk of breast cancer in the female twins, using male co-twin’s birth weight as an 
indicator of androgen exposure. 
 
 To examine whether associations between reproductive factors and risk of breast 
cancer are modified by genetic or early environmental factors. 
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4. Methodological considerations 
 
4.1 Registries  
4.1.1 The Medical Birth Register (MFR) (Studies І, ІІ, ІV) 
The Medical Birth Register (MFR), maintained by the Swedish National Board of Health and 
Welfare, includes prospectively collected information during pregnancy, delivery, and the 
neonatal period on virtually all births in Sweden since 1973 (241, 242). From 1973-1981, 
data were collected with a medical record form used by all antenatal care clinics, a form used 
by delivery units and a form for pediatric examination of offspring. The data from these three 
forms were summarized by a secretary in a single new form and sent to the National Board of 
Health for computerized storage. From 1982 onwards, copies of the three forms listed above 
were sent directly to the National Board of Health and Welfare (241). A report by MFR in 
2003 (242) showed that approximately 1.4% of all infants born in Sweden were not covered 
by this registry. Moreover, information on birth weight was a lacking in about 0.32% of 
cases. Information on placental weight, available only from 1982 to 1989, was missing for 
21% of single births during this period.   
 
4.1.2 The Swedish Quality Registry of Breast Cancer (SQRBC) (Studies І, ІІ) 
The Regional Quality Registries on Breast Cancer contain information collected since 1992 
in the six geographically defined health care regions of Sweden. This information includes 
tumor characteristics, such as stage at diagnosis (tumor size, lymph node involvement, and 
existence of distant metastases) and biological characteristics (grade and hormone (estrogen 
or progesterone) receptor status), diagnostic procedures and treatment. The Regional Quality 
Registries are validated with regards to the capture of incident breast cancer cases by 
comparison with the national Swedish Cancer Register (SCR), and are more than 95% 
complete (243). For tumor characteristics, completeness is highest in the quality registries 
covering the Stockholm-Gotland and Uppsala-Örebro regions in central Sweden.  
 
4.1.3 The Swedish Twin Registry (STR) (Study ІІІ) 
The Swedish Twin Registry (STR), maintained by the Department of Medical Epidemiology 
and Biostatistics, at Karolinska Institutet, was established in the late 1950’s. This registry, 
initially designed to investigate associations between cigarette smoking and alcohol 
consumption and cardiovascular disease and cancer, covers all twins born in Sweden since 
1886, in the form of an older (1886-1925), middle (1926-1958) and younger cohort (1959-
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present). Moreover, several questionnaires (administered in 1961, 1963, 1967, 1970 and 
1973), a telephone interview (SALT) conducted between 1998 and 2002 (244), the Study of 
Twin Adults: Genes and Environment (STAGE) on twins born from 1959-1985, another 
study on twin children born since 1992 (the Child and Adolescent Twin Study in Sweden, 
CATSS) and a third study in which birth information on all twins born from 1926 to 1958 
was collected were all used to complete the registry (245).  Zygosity is based on the extent of 
similarities between twins (intrapair similarities) during childhood, a procedure shown by 
DNA analysis to be 98% accurate or more (244).  
 
4.1.4 The Swedish Cancer Register (SCR) (studies ІІІ, ІV) 
The Swedish Cancer Register (SCR) has collected data on all cases of primary cancers in 
Sweden since 1958.  Reporting of newly detected cancer is obligatory for all health care 
providers in Sweden by law. Information on the pathology and cytology of cancers obtained 
from surgically removed tissue, bone marrow aspiration, biopsies, and autopsies are reported 
separately to this registry.  In addition to patient characteristics, including sex, age, place of 
residence and personal identification number, the medical information on the tumor includes 
the site, histology, stage and date of diagnosis. Moreover, follow-up data including date of 
death, cause of death or date of migration are added to this registry from the Swedish Cause 
of Death and Migration Registries(2). Approximately 98% of cases are verified 
morphologically(2). The SCR (243) is more than 98% complete (246) and is updated 
annually. Different editions of the International Classification of Diseases (ICD) have been 
used in the registry, but all have been translated to ICD-7 to enable studies of longer trends. A 
WHO method of coding pathology is used to record histological type, where applicable.  
 
4.1.5 The Swedish Cause of Death Register (SCDR) (studies І, ІІ, ІІІ, ІV) 
The nationwide Cause of Death Registey (SCDR) contains information on all deaths among 
Swedish residents since 1960. This information is based on death certificates filled in by 
trained physicians and contains the date of death, main and contributory causes of death, 
coded according to the ICD, 7
th–10th versions. This registry has been maintained by National 
Swedish Board of Health and Welfare since 1994 (247).   
 
4.1.6 The Multi-Generation Register (MGR) (Study ІV) 
The Multi-Generation Register, maintained by Statistics Sweden, collects information on all 
Swedish residents born after 1931 and still alive in 1961 as well as all those born thereafter. 
Thus, individuals born from 1932 and onwards are included in this registry (index persons). 
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The MGR contains information on the biological parents, siblings, children and cousins of 
index persons (2, 248). The completeness of the registry increased from 1961 to 2001, when 
it was considered complete since 2001 (249), covering information on 97% of mothers and 
95% of all index persons (248). 
 
4.2 The individual Studies 
 
All four studies were pre-approved by the Regional Research Ethics Committee at Karolinska 
Institutet. 
 
4.2.1 Study І 
4.2.1.1 Data collection 
Of all the women diagnosed with breast cancer during 1992 and 2006 (N=40,948), 8508 were 
diagnosed before menopause. All breast cancer information was extracted from the Regional 
Quality Registries of breast cancer for the Stockholm-Gotland and Uppsala-Örebro regions.  
After merging this information with data from MFR, excluding nulliparous women and 
women for whom information on placental weight was lacking, and restricting the study to 
the period 1982-1989, 1109 premenopausal parous women diagnosed with breast cancer 
remained. We subsequently excluded 8 women for whom information on gestational age was 
lacking, and 34 women with implausible information on placental weight. Of those excluded, 
24 were recorded as premenopausal on the basis of self-reporting at the time of diagnosis, but 
were 55 years old or older according to registries. In total, 1,067 women were finally eligible 
to be included and were followed until emigration, death or end of follow-up (December 31
st
, 
2008), whichever occurred first.  
 
4.2.1.2 Statistical analysis 
Cox regression analysis was used to estimate the hazard ratio (HR) between placental weight 
and risk of breast cancer mortality (with 95% confidence interval, CI) among premenopausal 
women. The follow-up period was the underlying time scale.  By including time-by covariate 
interaction in the model and testing for statistical significance, the assumption of 
proportionality was verified for all of these analyses. 
 
Placental weight was used as a continuous, as well as a categorical variable.  To ensure that a 
sufficient number of subjects and events had been included in each category, placental weight 
  33 
was divided into <600, 600-699 and ≥700 grams. First, the risk of mortality from breast 
cancer was estimated for the different categories of placental weight. Then, stratified analyses 
were performed to estimate this risk among different sub-categories of tumor characteristics. 
After these crude estimations, adjustments for gestational age (≤36, 37–38, 39–41, and ≥42 
weeks), parity (1, 2, 3, and ≥4), age at diagnosis (<30, 30–34, 35–39, 40–44, 45–49, and 50–
54 years), and level of education (less than high school, high school, and more than high 
school) were performed for all analyzes.  
 
To investigate interaction effects, placental weight (a categorical variable), tumor stage, ER 
and PR status, and tumor histology (categorical variables) were incorporated into the full 
models. To estimate the risk of mortality associated with placental weight while taking tumor 
characteristics into consideration, stratified analyses of subjects with tumors of different 
stages (0–1, 2, or 3–4), ER status (ER+, ER-), PR status (PR+, PR-), joint receptor status 
(ER+PR+, ER+PR-, ER-PR+, ER-PR-) and histology (Ductal, Lobular, Other) were 
performed.   
 
4.2.2 Study ІІ 
4.2.2.1 Data collection 
Using the SQRBC covering the Stockholm-Gotland region and Central Sweden, women who 
received a diagnosis of premenopausal breast cancer between 1992 and 2008 were identified. 
These registries include self-reported information concerning menopause. Through a linkage 
to MFR, all parous women diagnosed with premenopausal breast cancer before pregnancy 
(n=6,129) were included. Women with missing data on birth weight or gestational age 
(n=41), whose pregnancies ended with stillbirth (n=18), and twin pregnancies (n=51) were 
excluded, giving a final total of 6019 subjects with premenopausal breast cancer. The 
outcome was death due to all causes, recorded for approximately 99% of all deaths. We 
followed the subjects from the date of diagnosis until emigration, death or end of follow-up 
(December 31
st
, 2009), whichever occurred first. Information about vital status and dates of 
emigration was retrieved from the Swedish Population Register and the highest level of 
educational from the Education Register.  
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4.2.2.2 Statistical analysis 
The hazard ratio (HR) with 95% confidence interval (CI) was used as a measure of the 
association between BW/GA and risk of mortality from premenopausal breast cancer and was 
estimated using the Cox proportional hazards model. BW/GA was estimated using the 
Swedish reference curve for intrauterine growth and defined as the ratio of the observed to 
the expected. BW/GA was divided into <3, 3-9, 10-90, 91-97 and >97 percentiles.  
 
The association between PI and birth weight adjusted for gestational age was estimated, using 
the exposure as a continuous and categorized variable. PI was divided into percentile ranges 
analogous to the categorization of BW/GA. The association between birth weight and risk of 
mortality from breast cancer was estimated with the birth weight as a continuous or 
categorical variable (<3000, 3000-3499, 3500-3999 and ≥4000 grams). All models were 
adjusted for age at the time of diagnosis (<30, 30-34, 35-39, 40-44, 45-49, and 50-54 years), 
gestational age (≤36, 37–38, 39–41, and ≥42 weeks), parity (1, 2, 3, and ≥4), and level of 
education (less than high school, high school, and above high school).  
 
Maternal risks of mortality from breast cancer in relation to tumor stage (0-1, 2, or 3-4), 
estrogen receptor status (ER+, ER-), progesterone receptor status (PR+, PR-), joint receptor 
status (ER+PR+, ER-PR+, ER+PR-, ER-PR-) and histology (Ductal, Lobular, Other) were 
estimated by stratified analyses. To ensure a sufficient number in each sub-category, three 
stage categories were used instead of the five suggested by the American Joint Committee on 
Cancer (AJCC). The follow-up period was the underlying time scale. The assumption of 
proportionality was verified for all models by including time-by covariate interaction and 
testing for statistical significance. 
 
4.2.3 Study ІІІ  
4.2.3.1 Data collection 
Data on 13,075 opposite-sexed twin pairs with birth characteristics, born during the period 
1926-1972 were retrieved from the STR. Through linkage to the SCR, all twins with a 
diagnosis of breast cancer between 1972 and 2008 were identified and a nested case-control 
study was performed. Cases with breast cancer were individually matched to five female 
twins who were not affected by breast cancer by date of birth. Controls were alive when their 
counterpart case received the diagnosis of breast cancer. In total, 543 breast cancer cases and 
2,715 controls were included.  
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The birth weight of the cases, controls and co-twins was divided into <2000, 2000-2499, 
2500-2999, 3000-3499, and ≥3500 grams. The quartiles for birth height (≤46, 47-48, 49, and 
≥50 cm) and head circumference (<32, 32-33, 34-35, and >35 cm) were based on the 
distributions of these values among the control subjects. GA was categorized (<33, 33-36, 37-
39, and ≥39 completed weeks), and maternal age stratified as <25, 25-29, 30-34, and ≥35 
years. Maternal parity at the time of the subject’s birth was categorized as uniparous or 
multiparous. The maternal hypertensive diseases recorded during pregnancy included 
preeclampsia and eclampsia. Socioeconomic status was based on the father’s profession at 
the time of birth (unskilled blue-collar worker, skilled blue-collar worker, low-level white-
collar worker, intermediate-level white-collar worker, high-level white-collar worker or self-
employed). If information on the father’s profession was missing, the mother’s profession 
was used.  
 
4.2.3.2 Statistical analyses  
The association between birth weight and risk of breast cancer was estimated by conditional 
logistic regression. First, crude odds ratios (OR) and 95% confidence interval (CI) were 
estimated. Birth weight was considered both as a continuous (increase in risk per kg increase) 
and a categorical variable (<2000, 2000-2499, 2500-2999, 3000-3499, and ≥3500 grams) to 
estimate breast cancer risk. To decrease limitations due to the relatively small number of 
subjects in each category, we also reanalyzed the data using three categories of birth weight 
(<2500, 2500-2999 and ≥3000 grams).  
  
After executing this crude model, we consecutively adjusted for potential confounding factors 
in three different models, i.e., gestational age; then maternal age, parity and hypertensive 
disease during pregnancy; and finally socioeconomic status. The numbers of cases/controls 
for whom information concerning maternal parity and socioeconomic status was missing 
were 45/225 and 167/897, respectively. The association between co-twin birth weight, 
utilized as an indicator of the influence of androgen exposure, and breast cancer risk was also 
estimated, as was the association between the difference in the birth weights of the twin 
brother and sister (as a continuous or categorical variable (500 gram categories)) and breast 
cancer risk. Since the etiologies of pre- and postmenopausal breast cancer differ, theses 
analyses were stratified by age at the time of diagnosis, using 50 years as the boundary 
between pre- and postmenopausal breast cancer.  We used multiple imputation procedures to 
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deal with the missing values (250) and the Box–Tidwell test to examine possible nonlinearity 
of continuous variables. 
 
4.2.4 Study ІV  
4.2.4.1 Data collection  
In order to conduct a case-control study on possible modifying impact of familial factors on 
the association between early life events and risk of breast cancer, all women with singleton 
births in Sweden between 1973-2010 who had at least one full sister were identified from the 
MFR linked to MGR. By linking to the SCR, all women subsequently diagnosed with breast 
cancer at or before 50 years and who had a sister giving birth during the same period were 
selected for analysis. 
 
Both sisters and the general population were used as controls. Sister controls were parous 
sisters not diagnosed with breast cancer, closest in age to their sisters with breast cancer and 
alive at time breast cancer was diagnosed. All parous women in the study population who 
were not diagnosed with breast cancer and not a sister of a patient served as the population 
controls. In total, there were 8,349 cases, 8,349 sister controls, and 1,053,688 population 
controls. 
 
4.2.4.2 Statistical analyses  
To estimate the OR with 95% CI of breast cancer risk in association with birth and maternal 
characteristics, we used conditional logistic regression models or logistic regression models. 
The birth weight from the latest pregnancy was considered as a continuous and a categorical 
variable (<2500, 2500-2999, 3000-3499, 3500-3999, 4000-4499 and ≥4500 grams). We also 
estimated associations between BW/GA as a continuous and a categorized variable (<3, 3-
<10, 10-90, 91-97 and >97 percentiles) and breast cancer risk. Since infants within the 10-90 
percentiles are considered “Appropriate for Gestational Age (AGA)”, they were used as the 
reference group.  
Adjustments for maternal age at latest pregnancy (<25, 25-29, 30-34, 35-39,  ≥40 years), 
parity (1, 2, 3, and ≥4), level of education (below high school, high school, and more than 
high school) and date of birth (1973-1979, 1980-1989, 1990-1999, 2000-2010) were 
performed. Birth characteristics were also adjusted for these parameters plus GA (≤31, 32-36, 
37-38, 39-41 and ≥42 weeks). In addition to achieve a sensitivity analysis, the model for birth 
characteristics was adjusted for all variables used in the previous model, except GA.  
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Moreover, to control for potential confounders, we also adjusted for maternal height (<163, 
163-166, 167-170, ≥171 cm) and maternal BMI (<19, 19-24, 25-29 and ≥30) from 1983. No 
information on maternal BMI and maternal height was available for 1990 and 1991, and the 
percentage coverage for the other years ranged between 73 and 88%. We also analyzed the 
data from the perspective of first pregnancies during the study period (n=6,945) to study any 
association between age at first pregnancy and premenopausal risk of breast cancer.  
 
All analyses were performed using the SAS software (SAS Institute, Cary, NC, USA). 
 
5. Results 
5.1 Study І 
The major finding was that the association between placental weight and higher risk of 
mortality from breast cancer is more pronounced for women with ER-/PR- tumors. The crude 
RR for higher maternal mortality was statistically significant for women with a placental 
weight between 600 and 699 grams in their last pregnancy before diagnosis (Table 4), but a 
heavier placenta did not increase breast cancer mortality risk. A stratified crude and adjusted 
analysis revealed a significant association between placental weight and mortality from breast 
cancer for women with tumors in stage 3 or 4. Moreover, women with ER- or PR-negative 
tumors and a placental weight between 600-699 grams exhibited a higher risk of mortality 
from breast cancer. Subsequent analysis revealed that this association is more pronounced 
among women with ER-/PR- tumors (Table 5).    
 
Table 4: Crude hazard ratios (HR) and 95% confidence interval (CI) for the association between placental 
weight and breast cancer mortality. Parous women with  premenopausal  breast cancer diagnosed from1992 
through 2006 
 Subjects  Events  Crude HR (95% CI) 
Total 1067 180  
Placental weight, grams    
<600 458 70 Referent 
600-699 322 69 1.49 (1.07-2.08) 
≥700 287 41 0.90 (0.61-1.32) 
Continuous (50 gram) 1067 180 1.00 (0.94-1.05) 
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 Table 5: Crude and adjusted hazard ratios (HR) and 95% confidence interval (CI) for the association 
between placental weight and breast cancer mortality among premenopausal women with estrogen- and 
progesterone- negative tumors whose last pregnancy occurred during the period 1982-1989. 
 Subjects Events Crude 
HR (95% CI) 
Adjusted 
HR(95% CI)* 
Placental weight, gram     
<600 56 9 Referent Referent 
600-699 48 16 2.29 (1.01-5.18) 2.69 (1.12-6.47) 
≥700 44 18 3.06 (1.37-6.82) 3.86 (1.56-9.57) 
Continuous (50 gram) 148 43 1.15 (1.02-1.30) 1.17 (1.03-1.32) 
* Adjusted for gestational age, parity, age at diagnosis, and level of education 
 
We found that the maternal risk of breast cancer mortality was reduced with more advanced 
age at the time of diagnosis and higher level of education. Moreover, women diagnosed with 
breast cancer less than 10 years after their last pregnancy had a higher risk of dying than 
those diagnosed later. As expected, a higher tumor stage, lack of both estrogen and 
progesterone receptors, were also associated with higher breast cancer mortality. We found 
no influence of GA, parity and age at first pregnancy on this risk in premenopausal women. 
In interaction analysis, we found significant association between placental weight and ER 
status and risk of breast cancer mortality (p<0.01), and a similar interaction was also found 
for PR status (p<0.0001). 
  
5.2 Study ІІ  
We found no statistically significant association between offspring birth weight and maternal 
risk of mortality from breast cancer, neither in the crude analysis, nor in the adjusted analysis. 
Application of BW/GA showed a higher risk of women whose children had the lowest values 
(<3%) in the adjusted analysis (Table 6). There was no association between PI and maternal 
risk of mortality from breast cancer. The elevated risk among the women with the smallest 
offspring was restricted to those with cancer diagnosed 5–9 years after the pregnancy, 40 
years or younger at the time of diagnosis and with stage 2 and/or ER-positive tumors.  
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Table 6: Crude and adjusted hazard ratios (HR) and 95% confidence intervals (CI) for the association 
between offspring birth weight and birth weight for gestational age and the maternal risk of breast cancer 
mortality. Premenopausal parous women diagnosed with breast cancer from 1992-2009 in Sweden. 
 Subjects Events Crude HR 
(95% CI) 
Adjusted HR 
(95% CI)a 
Birth weight (grams)     
<3000 783 132 1.07 (0.88-1.31) 1.12 (0.90-1.40) 
3000-3499 1862 330 1.12 (0.96-1.30) 1.13 (0.97-1.32) 
3500-3999 2162 337 Referent Referent 
4000-4499 971 181 1.18 (0.99-1.41) 1.16 (0.97-1.40) 
≥4500 241 37 1.04 (0.74-1.45) 1.06 (0.75-1.49) 
P for trend   0.42 0.42 
Continuous (100 grams) 
 
6019 1017 1.00 (0.99-1.01) 1.00 (0.99-1.01) 
Birth weight for gestational age  
percentiles  
 
<3 132 33 1.52 (1.07–2.15) 1.55 (1.09–2.21) 
3-<10 294 60 1.15 (0.89-1.50) 1.09 (0.84-1.42) 
10-90 4865 801 Referent Referent 
91-97 493 88 1.08 (0.87-1.35) 1.12 (0.90-1.39) 
>97 231 35 1.00 (0.71-1.40) 1.05 (0.75-1.48) 
Continuous 6015 1017 0.97 (0.91-1.02) 0.99 (0.93-1.04) 
Information missing  4 0   
Quadratic analysis   1.03 (1.00-1.06) 1.04 (1.01-1.07) 
a
Adjusted for gestational age, parity and level of education 
 
Estimation of the crude and adjusted hazard ratios for pregnancy characteristics and maternal 
risk of premenopausal breast cancer mortality revealed that lower age at the time of 
diagnosis, a lower level of education and a shorter period between the last pregnancy and 
diagnosis of breast cancer were associated with higher risks. Moreover, higher tumor stage, 
lack of ER and PR, in particular an ER-/PR- phenotype were associated with higher maternal 
mortality of breast cancer. Restricting the analysis to women born in Nordic countries (i.e., 
Sweden, Denmark, Finland, Iceland, and Norway) did not influence the results. 
 
5.3 Study ІІІ  
In the study of females from opposite-sexed twin pairs, we found no significant associations 
between birth weight and subsequent risk of breast cancer, neither for premenopausal (Table 
7) nor postmenopausal women (Table 8).  
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Table 7: Crude and adjusted odds ratios (OR) and 95% confidence interval (CI) for the association between birth weight and risk of 
breast cancer in females of opposite-sexed pairs. Swedish twins born from1926-1985 and diagnosis at or before 50 years of age* 
 No. 
(case/control) 
OR (95% CI) 
Crude 
OR (95% CI) Model 
1 
OR (95% CI) 
Model 2 
OR (95% CI)  
Model 3 
Birth weight, gr     
<2000 17/77 1.11 (0.62-1.98) 1.11 (0.59-2.09) 1.09 (0.58-2.06) 1.08 (0.57-2.04) 
2000-2499 59/262 1.06 (0.72-1.55) 1.10 (0.74-1.63) 1.09 (0.73-1.62) 1.07 (0.72-1.60) 
2500-2999 74/372 Referent Referent Referent Referent 
3000-3499 40/222 0.81 (0.53-1.25) 0.84 (0.54-1.30) 0.84 (0.54-1.30) 0.83 (0.53-1.30) 
≥3500 13/42 1.56 (0.80-3.05) 1.70 (0.85-3.40) 1.72 (0.86-3.44) 1.75 (0.87-3.53) 
Overall, Kg 203/975 0.95 (0.70-1.31) 0.99 (0.69-1.42) 1.02 (0.71-1.47) 1.01 (0.70-1.46) 
*Multiple imputation analysis was used to deal with missing data. 
Model 1: Adjusted for gestational age  
Model 2: Adjusted for gestational age, maternal age, parity and hypertensive disease during pregnancy.  
Model 3: Adjusted for the variables in Model 2 and social economy status.   
Table 8: Crude and adjusted odds ratios (OR) and 95% confidence interval (CI) for the association between birth weight and risk of 
breast cancer in females of opposite-sexed pairs. Swedish twins born from 1926-1985 and diagnosed after 50 years of age * 
 No. 
(case/control) 
OR (95% CI) 
Crude  
OR (95% CI) 
 Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
 Model 3 
Birth weight, gr      
<2000 26/133 0.88 (0.56-1.40) 0.85 (0.52-1.40) 0.84 (0.51-1.38) 0. 84 (0.51-1.38) 
2000-2499 97/508 0.88 (0.66-1.17) 0.85 (0.63-1.14) 0.85 (0.63-1.15) 0. 86 (0.64-1.16) 
2500-2999 138/645 Referent Referent Referent Referent 
3000-3499 64/382 0.78 (0.56-1.08) 0.79 (0.57-1.09) 0.78 (0.56-1.09) 0.77 (0.55-1.08) 
≥3500 15/72 0.97 (0.54-1.75) 0.98 (0.54-1.78) 0.98 (0.54-1.79) 0.99 (0.54-1.80) 
Overall, Kg 340/1740 0.97 (0.77-1.24) 1.03 (0.79-1.35) 1.03 (0.78-1.36) 1.03 (0.78-1.36) 
*Multiple imputation analysis was used to deal with missing data. 
Model 1: Adjusted for gestational age   
Model 2: Adjusted for gestational age, maternal age, parity and hypertensive disease during pregnancy.   
Model 3: Adjusted for the variables in Model 2 plus socioeconomic status.   
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Furthermore, there were no associations between birth height, head circumference, GA, 
maternal age, maternal parity and hypertensive disease during pregnancy and risks of 
premenopausal or postmenopausal breast cancer. We found no association between co-twin’s 
birth weight and risks of pre- or postmenopausal breast cancer risk.  In addition, there were 
no significant associations between the difference in female and male birth weight (as a 
continuous or categorical variable) and risk of premenopausal or postmenopausal breast 
cancer, even after application of the multiple imputation procedure to deal with missing data.   
 
5.4 Study ІV  
In crude analyses, we found that higher parity increased breast cancer risk, using population 
controls, and, in particular, when using sister controls. In the adjusted analyses, there was 
inverse association between parity and breast cancer risk when population controls were used, 
whereas high parity was directly associated with an increased breast cancer risk when the 
sister controls were used (Table 9). Extreme prematurity was associated with higher risk, 
especially in comparison to the sister controls. A high maternal age at the last pregnancy was 
associated with a higher risk of premenopausal breast cancer, both when population and sister 
controls were used.  
We found no noteworthy differences in the association between offspring birth weight, birth 
height, BW/GA and risk of premenopausal breast cancer when population and sister controls 
were used. A statistically significant inverse association was found between preeclampsia and 
risk of breast cancer risk using population controls, but not when using sister controls.  
Two additional multivariable models that exclude GA or adjust for BMI and maternal height 
resulted in no noteworthy change in the associations between offspring characteristics and 
risk of breast cancer.  In a sub-analysis, we found that a shorter maternal height and higher 
BMI in last pregnancy were associated with a lower risk of breast cancer using population 
controls, but not when using sister controls.                                     
  
 
  
 42 
Table 9: Crude and adjusted Odds Ratio (OR) and 95% confidence interval (95% CI) for the association between parity and 
the risk of breast cancer in Swedish women diagnosed at the age 50 or younger during 1973-2010 in comparison to both 
population and sister controls.  
 Cases of breast cancer 
Total n=8,349 
Population controls 
Total n=1,053,688 
 
 
Sister Control 
Total n=8,349 
 
 
 Number Percent Number Percent OR(95% CI) Number Percent OR(95% CI) 
Parity          
1 1444 17.3 196605 18.7 Referent 2779 3333 Referent 
2 4218 50.5 517930 49.2 1.10 (1.04-1.78) 3407 8.34 2.43 (2.24-2.63) 
3 2068 24.8 249519 23.9 1.13 (1.06-1.21) 1598 1.31 2.59 (2.35-2.85) 
≥4 619 7.4 89634 8.5 0.94 (0.86-1.03) 565 834 2.19 (1.90-2.52) 
Parity a         
1 1,444 17.3 196605 18.7 Referent 2,779 3333 Referent 
2 4,218 50.5 517930 49.2 0.91 (0.86-0.97) 3,407 8.34 2.21 (2.03–2.40) 
3 2,068 24.8 249519 23.9 0.76 (0.71-0.82) 1,598 1.31 2.13 (1.92–2.36) 
≥4 619 7.4 89634 8.5 0.56 (0.51-0.62) 565 834 1.72 (1.48–2.00) 
a
 Adjusted for maternal age at last pregnancy, parity, level of education and calendar year 
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6. Discussion 
6.1 Methodological considerations 
Epidemiology is defined as the study of the distribution and determinant of states and events 
in the human population, including health-related states and events (251). This definition 
encompasses not only disease and negative outcomes, but also physiological status such as 
blood pressure or reproductive status, as well as positive outcomes such as immunity or 
normal birth. The main aim of epidemiologic studies is to establish an accurate and valid 
estimation of the effects of some exposures on an outcome, using different approaches.  
Epidemiological studies can be divided into two major groups: experimental investigations, 
including randomized controlled trials and quasi-experimental; and observational approaches 
consisting of case reports or case series, case-control, cohort, cross-sectional and ecological 
studies. Experimental studies involve comparison of at least a group subjected to the 
intervention (exposed) and another subjected (unexposed), in attempt to determine the impact 
of the intervention on the outcome(s) of interest. These groups are formed in a random and 
blinded fashion to reduce bias and confounding. In a single blinded trial, the participants 
receive no information about who is receiving the intervention; in a double-blinded trial 
neither the subjects nor researchers know; and in a triple-blinded the individuals who analyze 
the data do not know either.  
Although experimental studies provide strong evidence of causality with low probability of 
bias, they are expensive and time-consuming. Nonetheless, the experimental approach (in 
humans, the Randomized Clinical Trial (RCT)) is considered the gold standard in 
epidemiological studies. For ethical reasons, humans can only be subjected to potentially 
beneficial interventions.  
Non-experimental studies can help to avoid possible risks and achieve results of good 
accuracy. However, such studies are prone to a variety of potential biases or confounders.    
6.1.1 Study designs 
Non-experimental studies can be observational or analytical. Observational approaches 
include estimating the incidence or prevalence of a disease or the side effects of a drug or a 
surgical procedure. In one type of observational studies, referred to as ecological, data is 
collected on a group/community, but not on individuals; by comparing exposure, and 
outcomes at this level, a hypothesis can be created.  In analytical studies, such as case-control 
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or cohort studies, the association between an exposure of interest and a particular outcome is 
estimated at the individual level.   
 6.1.1.1 Case-control design 
Case-control studies begin by identifying cases and the study population should be defined 
exactly before case selection. All who fulfill the criteria for inclusion should be included. 
Cases can be identified from a registry, a vital record or a defined geographical area 
(population-based) or on the basis of information collected by hospitals or clinics (hospital-
based). The controls should be representative of the community regarding the prevalence of 
exposure and should therefore be selected from the same population as the cases. 
Alternatively, when this is not possible, controls can be selected among relatives, neighbors 
or friends of the cases, although such groups might not be representative of the community. 
Comparison of the odds of being exposed in the case and control groups is appropriate for 
rare diseases or for a disease with a long latency period. Case-control studies are less 
expensive and can be conducted in a shorter time than cohort studies, but are commonly 
prone to certain types of bias, such as recall or selection bias. Moreover, selecting a 
representative control group can be difficult.   
Matching is one method for improving the validity and efficiency of this type of 
investigation.  Matching makes cases and controls as similar as possible with regards to one 
or more characteristics/confounding factors, thereby controlling for important confounders. 
Matching can be done at the individual level, where one or more controls are matched with 
each case, or at the frequency level, where a group of controls is matched with a group of 
cases. In study three, we matched five controls to each patient with breast cancer on the 
individual level with respect to the year of birth, and also required the controls be alive at the 
time when their matched cases were diagnosed with breast cancer.  
6.1.1.2 Nested-case control design 
Nested-case control studies can be conducted when the cohort is well-defined, avoiding the 
issue of selection bias. Thus, with this approach, cases diagnosed during follow-up are 
included and one or more controls randomly selected at the time of diagnosis. Moreover, the 
probability of information bias is also low, because the information about exposure is 
collected before the outcome develops. A nested case-control study can be conducted when: 
a) more information is required after completion of data collection in a cohort study and 
collecting more data from all the study participants is expensive, b) when recollecting more 
data from all the cohort participants is technically impossible, or c) when performing a 
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particular procedure e.g., in the laboratory for an entire cohort population is expensive or 
even impossible for technical reasons.  
 
 In study three, we applied a nested case-control approach to a well-defined cohort of female 
twins of opposite-sexed twin pairs. We included all female twins diagnosed with breast 
cancer during the study period and for each case randomly selected five controls among 
female twins not diagnosed with breast cancer, employing matching with respect to the year 
of birth and requiring that the controls be alive at the date diagnosis of breast cancer in 
corresponding case. 
 
6.1.1.3 Cohort design 
A cohort study involves one group of individuals exposed to some factors of interest (the 
exposed group) and another not exposed group (the unexposed group). In this case, the 
subjects have not yet developed the outcome in focus and are monitored for this 
development. Comparing the occurrence of the outcome in both groups will provide the risk 
ratio for occurrence of this particular outcome due to the exposure of interest.  
 
Cohort studies can be applied when the exposure of interest is rare or when you want to 
examine two or more outcomes. Subjects are selected and exposure status recorded before 
detection of the outcome.  However, cohort studies are usually expensive, time-consuming, 
and inappropriate for rare outcomes.  Lack of follow-up is also a concern here.   
 
Studies one and two in the present thesis have cohort designs. In both cases, we individually 
linked information from existing data sources (registries). Since data was already collected, 
this was both an efficient and inexpensive procedure. In study one, placental weight from 
1982 to 1989 was the main exposure (242) and in study two, the main exposure was birth 
weight (242). In both studies, the outcome was death due to all causes. We also utilized 
information about tumor characteristics from two regional quality registries of breast cancer 
in central Sweden covering a population of more than 4 million populations.  
 
6.1.2 The validity of study 
A causal association can be inferred by employing some criteria such as Hill’s criteria of 
causal inference (252). Epidemiological estimation of an association should be valid and 
precise. Validity, defined as how closely we measured what we intended to, is of two types: 
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internal validity is violated by selection bias, information bias or confounding, while external 
validity concerns generalizability to other populations.  
 
6.1.2.1 Internal validity 
6.1.2.1.1 Selection bias  
Selection bias, which arises from inappropriate selection of subjects or factors which 
influence participation (10), involves a differences between eligible participants in a study 
and those who are eligible but do not participate. This is a concern in connection with case-
control studies. Cohort studies are less prone to selection bias, since subjects are selected on 
the basis of their exposure and prior to occurrence of the outcome.  
 
In study one, we selected all parous women whose placental weight was available, and 
excluded women for whom such information was lacking. Given possible difference between 
eligible samples who were excluded and who were included in the study, we used multiple 
imputation method. We found no noteworthy difference between the two results.  
  
In study three, we selected all female members of opposite-sexed twins diagnosed with breast 
cancer as cases and for each case, 5 female twins not diagnosed with breast cancer were 
selected as controls. In study four, we had two control groups, i.e., sister and population 
controls. Sisters with closest in age to the cases constituted the sister control group, while, the 
population controls were all women without breast cancer and not included in the sister 
control group.   
  
6.1.2.1.2 Information bias 
Information bias involves incorrect measurement of the exposure and/or outcome and usually 
leads to misclassification. Misclassification may be non-differential and differential. If the 
probability of being misclassified is the same for all classes or categories of a variable and for 
all subjects, it is referred to as non-differential misclassification. For example, measuring 
birth weight with a scale that is 100 grams off or categorizing esophageal cancer in subgroups 
which exhibit some overlap in diagnosis can be referred to as non-differential 
misclassification. Differential misclassification is based on the value of other study variables 
(253). When the probability of being misclassified is not the same for all classes or 
catergories of a variable  and for all subjects, it is refered to as differential misclassification. 
For example, recall bias give rise to differential misclassification as explained below. Both 
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types of misclassifications can influence the results. Non-differential misclassification may 
lead to that differences will be diluted out and the results move toward no difference (null) if 
the exposure is dichotomous. If the exposure is categorical, the result may move towards or 
away from null, depending on which category was misclassified (253). In the case of 
differential misclassification, the result can move towards or away from null (253).  
 
Recall bias occurs most frequently in case-control studies, when information on exposure is 
collected after the outcome: participants are asked to recall what had happened to them before 
occurrence of the outcome. If the accuracy of cases and controls in recalling events differs, a 
differential misclassification can be present. For example, when a mother of an affected 
offspring is asked to recall what happened before or during her pregnancy, she may 
remember more details about her pregnancy and its complications than a mother with an 
unaffected offspring. Since we collected the data on exposure before the occurrence on the 
outcome, recall bias was not a concern in our studies.   
 
Imperfect measurement of exposure, outcome and/or potential confounding factors can also 
lead to information bias. In study one, placental weight was the main variable of interest in 
relationship to maternal risk of breast cancer mortality. Several factors can influence the 
measurement of placental weight, including time at which the umbilical cord is cut, and the 
scale used for weighing. Cutting the umbilical cord sooner or later after delivery influences 
how much blood remains in the placenta. Moreover, the length of the umbilical cord left after 
cutting can influence the weight of the placenta. Although guidelines for these procedures 
probably exist, these may vary between hospitals. The midwife doing the weighing and the 
scale used may also exert an impact on the weight obtained. This can lead to non-differential 
misclassification.  
  
We employed placental weight and birth weight as indirect (proxy) indicators of estrogen 
levels during pregnancy. Proxies are likely to be influenced by a variety of other factors, 
thereby increasing the risk of misclassification. For example, placental weight is dependent 
on maternal size, size of the uterus, parity, weight gain during pregnancy, or diseases 
contracted during pregnancy, such as diabetes and hypertension. Offspring birth weight is 
dependent on genetic factors, maternal size, parity, gestational age and disease occurring 
during pregnancy, such as gestational diabetes or hypertension. Such factors may results in 
non-differential misclassification, especially if the proxies are considered to be categorical 
variables.  
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Another exposure which has been affected by measuring error is gestational age. Based on 
the time that elapsed between the first day of LMP and date of delivery, determination of GA 
may easily involve recall bias. Moreover, some cases of breast cancer might be missed or 
diagnosed incorrectly. The outcomes can be misclassified as well. In studies 1 and 2, the 
outcome of mortality due to all causes was checked in the Cause of Death Register and found 
to be about 99% complete.  
 
6.1.2.1.3 Confounding  
Confounding involves confusing or mixing up the effect of one exposure with the effect of 
another variable (253). Confounders are risk factor for the outcome, associated with the 
exposure and not an intermediate between the exposure and outcome. A confounder can lead 
to overestimation or underestimation of an association or even alter its nature, e.g., from 
positive to negative.  
 
In studies 1 and 2, the potential confounders were GA, parity, age at diagnosis and level of 
education, which we adjusted for in our models. Nonetheless, there might have been some 
residual confounding. In examining a potential association between placental weight or birth 
weight and breast cancer mortality, we also performed analyses restricted to different 
subcategories of tumor characteristics to control for potential confounding by tumor 
characteristics. Since we did not have information about smoking and diseases during 
pregnancy, such as hypertension or diabetes, these factors could not be taken into account.  
 
In study 3, we used different models to estimate the association between breast cancer risk 
and offspring birth weight in opposite-sexed twins and also matched cases and controls with 
respect to their year of birth. In one model, we adjusted for GA; the second adjusted for GA, 
maternal age, parity, and hypertensive disease during pregnancy; and third adjusted for all the 
same variables as in the second model plus socioeconomic status.  
 
In study four, we adjusted our models for maternal age at last pregnancy, parity, level of 
education, calendar year and gestational age. We also performed an additional analysis with 
adjustment for GA.  
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6.1.2.1.4 Random error or chance  
Although the possibility of random error, i.e., what remains after elimination of systematic 
error (253), cannot be totally excluded, statistical procedures can be applied to estimate the 
role played by chance in the results. Observed determination of the P-value (i.e., the 
probability of the occurrence of a result as extreme as or more extreme than if the null 
hypothesis is true) is one such approach. More informative is to estimation of the confidence 
interval (CI), i.e., a range of values which contain the true measure with 95% probability. 
Random error is related to the precision of the study. The most effective way to deal with 
random error is by increasing sample size, thereby decreasing such random error and 
increasing the precision and power of the study.  
The studies described in this thesis involved relatively large populations and, as we 
calculated, reasonable statistical power for estimation of the main association. However, 
stratified analyses reduced the number of subjects in certain subcategories, thereby reducing 
statistical power. In study one, the sample size for estimating the association between 
maternal risk of mortality and placental weight in relation to subcategories of tumor 
characteristics was small. Therefore, we divided the tumors into three stages instead of four. 
In study 2, the numbers of events in certain subcategories, e.g., ER/PR subgroups were small. 
Studies 3 and 4 were large, and limited statistical power was not an issue.  
 
6.1.2.2 External validity (generalizability) 
External validity or generalizability, i.e., the possibility of extending the results of an 
investigation to a larger population, depends (assuming internal validity) on various factors, 
including biological interaction. Study 3 involved twins and there might be differences 
between twins and singletons that could influence the finding obtained. For example, twins 
exhibit a different pattern of growth during pregnancy (254) and have less physical space in 
the uterus. Moreover, twins and singletons appear to differ with respect to subsequent 
diseases in adulthood (255-257). Accordingly, the generalizability of the results of study 3 
still can be questioned. However, most studies suggested that there is no difference between 
twins and singeltons.  
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6.1.3 General discussion 
This thesis includes four epidemiological studies investigating associations between indirect 
indicators of pregnancy hormone exposure and breast cancer risk and survival, with special 
emphasis on young breast cancer patients.  
In the first study, we found an association between placental weight and maternal risk of 
mortality from breast cancer which was more pronounced among women with ER-/PR- 
tumor receptive status. Previously,  investigators have suggested that breast cancer tumors 
should be categorized on the basis of their expression of both ERs and PRs, rather than 
individual expression (207). ER-/PR- tumors are more frequent in premenopausal breast 
cancer, whereas in postmenopausal breast cancer ER+/PR+ tumors are more frequent (71, 
207, 258, 259). In addition, ER-/PR- tumors demonstrate higher proliferation rate (197, 258, 
260), more advanced stage (71, 207, 258), and higher proportion of cells in S-phase (260, 
261).  
The expression of receptors is more dependent on age (71, 204, 205, 208, 229, 262-264) than 
on menopausal status. In fact, the incidence of ER- breast cancer increases with age during 
the premenopausal period, reaching a constant level after 50 years of age; while the greatest 
incidence of ER+ tumors occur after 70 years (204, 208). Certain reports document 
statistically significant higher frequency of ER-/ PR- tumors among cases of pregnancy-
related breast cancers (163, 166). Therefore, it can be suggested that premenopausal 
hormonal exposure exerts a greater impact on receptor-negative than on receptor-positive 
tumors. However, the biological mechanisms underlying the elevated breast cancer mortality 
risk observed among patients with ER-/PR- tumors and higher placental weight remain to be 
explained.  
The findings of study one is consistent with previous findings (42, 71, 189, 201, 228, 240, 
265) that breast cancer mortality among premenopausal women with ER-/PR- tumors is 
higher than for those with ER+/PR+ tumors. Dunnwald and colleagues (228) observed that 
premenopausal women with ER+/PR-, ER-/PR+, or ER-/PR- tumors all experienced higher 
risks for breast cancer mortality than those women with ER+/PR+ tumors. These differences 
were largely independent of demographic and clinical tumor characteristics, and ER-/PR- 
tumors conferred the highest risk. Examining ER+/PR- and ER-/PR+ tumors can be 
problematic due to their low incidence (71, 207, 231, 259). It has been proposed that estrogen 
and ERs are required for the synthesis of PRs, and that identification of  ER-/PR+ tumors 
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may be  laboratory mistake (266). In addition, receptor-positive tumors can become receptor-
negative with time (267).  
Lukanova and co-workers (108) reported that higher levels of estrogen during the first 
trimester was associated with an enhanced risk of breast cancer, and also reported a higher 
proportion of receptor-negative tumors among women diagnosed before the age of 40, 
observations consistent with our own results. Animal experiments showing that even ER- 
breast cancer tumors require estrogen for their formation and progression (238) have led to 
speculation about a direct association between estrogen levels and such tumors. However, in 
certain other investigations (268) there was no clear association between estrogen levels in 
the third trimester of pregnancy and risk of breast cancer. In addition, a recent large cohort 
study did not find any association between placental weight and breast cancer risk (269).  
In the second study, we observed no association between birth weight and risk of 
premenopausal breast cancer mortality, not even when taking tumor characteristics into 
consideration. These findings are not consistent with those of the first study, where high 
placental weight was associated with increased risk, an association which was modified by 
tumor characteristics. The placenta is the primary source of pregnancy hormones and 
placental weight might be a more robust and independent indicator of hormone exposures 
during pregnancy than birth weight (270), which could explain these inconsistencies.  In 
another investigation, the effect of offspring’s birth weight on mother’s risk of 
premenopausal breast cancer disappeared after adjusting for placental weight (36).  
In addition, birth and/or placental weight could be markers for other exposure(s) that might 
influence cancer mortality. For example, a disproportionately large placenta might reflect the 
presence of a chronic process requiring placental overgrowth, such as maternal anemia or 
malnutrition (271), but whether this would influence breast cancer mortality is unknown. 
Moreover, our finding of enhanced maternal risk of mortality among those giving birth to 
small-for-gestational age offspring was restricted to uniparous women. We speculate that this 
finding might be due to comorbidities in the mother, such as autoimmune diseases (272, 273), 
or to other risk factors such as cigarette smoking (274), which could affect both offspring 
birth weight and mortality.  
The third study revealed no association between birth weight and the risk of pre- or 
postmenopausal breast cancer among the female members of opposite-sexed twins, a finding 
consistent with several earlier cohort (87, 88, 90) and case-control studies (65, 66, 89, 275-
278). However, many investigations, including two recent meta-analyses (75, 279) and a re-
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analysis of 32 previous studies (76) conclude that a high birth weight is associated with a 
modestly increased risk of breast cancer (77, 78, 80, 81, 86, 280), but the association may be 
restricted to premenopausal breast cancer (77, 80-86, 280). However, many published studies 
suffer from a limited sample size. Among women with high birth weight, we also observed a 
more than 1.7% increased risk of premenopausal breast cancer, but this effect is not 
statistically significant.  
 
There is only one other investigation on the potential association between birth weight and 
breast cancer risk in opposite-sexed twins (73). Kaijser and colleagues  (73) found that the 
risk of breast cancer was 12-fold higher among female twins with a birth weight of more than 
3,500 grams than among those whose birth weight was 2,000 grams or less. However, the 
sample size was small (only 90 breast cancer cases) and study period was relatively short.  
 
In two other Swedish twin studies, the potential association between birth weight and breast 
cancer risk within like-sexed twin pairs was examined. In the small case-control study, a non-
significantly  higher risk was present among the twins with the higher birth weight (276); 
while in the larger, more recent investigation, this difference was on statistically significant 
for premenopausal breast cancer (85). Our birth cohort was of wider range (1926-1972) and 
the study period longer (1972-2008) than in these two studies of like-sexed twins. Since a 
statistically significant positive association between birth weight and premenopausal breast 
cancer was observed in the larger study of like-sexed twins (85) but not by us, we speculate 
that prenatal exposure to androgens may also be important for breast cancer risk. However, 
we observed no effect of male co-twins birth weight (possibly also reflecting prenatal 
exposure to androgens). The interactions between maternal, placental and fetal steroid 
production and exchange are complex and not completely understood (281). 
In the fourth study, multiparous women demonstrated a higher risk of premenopausal breast 
cancer than uniparous women when the sister controls were used for analysis. In contrast, 
when population controls were used, this association was the inverse, suggesting a gene-
environmental interaction. These findings are consistent with previous reports (282-285). One 
previous study report that higher parity is associated with an increased risk of premenopausal 
breast cancer when sister controls are used, but not when population controls are used (283). 
Another case-control study (282) demonstrated that the protective effect of parity was present 
among women without a family history of breast cancer but not among women with such a 
family history and that parity interacted with genetic effects.   
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Very preterm delivery was associated with a higher breast cancer risk, and to a greater extent 
using sister than population controls.  This result is consistent with previous finding of higher 
risk of breast cancer among mothers who delivered at lower gestational age (59, 60). Another 
investigation (59) has reported that the risk of breast cancer was two times higher among 
those with very preterm delivery than those delivering after 36 weeks of pregnancy. In 
addition, Melbye and co-workers (60) showed that among women younger than 50 years, the 
risk of breast cancer was 72% higher for those who had ever delivered at 31 weeks of 
gestational age or earlier than for other parous women.  
One hypothesis in this context is that since mammillary cells proliferated during the first and 
second trimesters of pregnancy and differentiate during the third, shortening pregnancy 
maintains the proliferation of these cells, which might increase the risk of breast cancer (61). 
The higher risk of premenopausal breast cancer observed using sister controls suggests a 
gene-environmental interaction, i.e., a different effect of parity or a related factor on the risk 
of premenopausal breast cancer in women with different genotypes.   
The association between risk of premenopausal breast cancer and maternal characteristics, 
including maternal age at last pregnancy and BMI, were not confounded by familial factors. 
Higher maternal age at last pregnancy was associated with an increased risk of 
premenopausal breast cancer in both control groups, which is consistent with most previous 
findings (39, 286), but not all (287). There was inverse association between maternal BMI in 
the last pregnancy and the risk of premenopausal breast cancer, which is also consistent with 
previous reports (36, 48, 49). 
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7. Conclusion 
 Our findings provide some support for the hypothesis that hormone levels during 
pregnancy influence premenopausal breast cancer mortality, and that this association 
is influenced by tumor receptor status. 
 
The increased risk of mortality from ER-/PR- tumors associated with higher placental 
weight suggests that premenopausal hormonal exposure might exert a greater impact 
on such tumors. 
 
 The hypothesis that ‘‘premenopausal breast cancer mortality is associated with 
offspring birth characteristics in connection with the most recent pregnancy before 
diagnosis’’ may not be true. In addition, any such association is not modified by 
tumor characteristics. 
 
 Higher offspring birth weight is not associated with offspring’s subsequent risk of 
breast cancer.  
 
The association between birth weight and risk of breast cancer is not influenced by 
the birth weight of the male co-twins.  
 
 The association between parity and gestational age and risk of premenopausal breast 
cancer may be influenced by a gene-environment interaction.   
 
 The association between other reproductive factors and risk of premenopausal breast 
cancer was not confounded by familial factors 
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8. Final remarks and future perspectives  
 
Breast cancer is the leading form of cancer among women world-wide, and identification of 
risk and prognostic factors could be of enormous value in improving the prevention and 
treatment of this disease. The present thesis has tried to answer some relevant questions, but 
several new questions have also been raised. Future studies should include the following:  
 
- Performing a study with much bigger sample size investigating the potential 
association between placental weight and mortality from premenopausal breast 
cancer.  
 
- Employing the st. Gallen classification method to determine whether the association 
between premenopausal breast cancer mortality and reproductive factors is influenced 
by tumor characteristics. 
 
- The higher risk of maternal mortality from breast cancer observed in association with 
very preterm delivery in study two should be explored in more detail on a larger 
population.    
   
- The main focus here was on premenopausal breast cancer and postmenopausal breast 
cancer deserves similar attention. 
 
 
- In light of the more rapidly increasing and higher rate of mortality from breast cancer 
in low-income countries, analogous studies should be performed in these areas.  
 
Studies which needs collaboration with other research groups: 
 
- Many reproductive factors are associated with breast cancer risk and mortality but the 
underlying mechanism(s) remain to be elucidated.  
 
- The associations with certain risk factors (e.g. placental weight) only in specific 
subgroups of tumors observed here should be confirmed using a larger population and 
the underlying mechanism(s) unraveled. 
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